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There are approximately 22,200 new cases of ovarian cancer (OC) within the US each year. The 
overall 5-year survival rate for OC is 44%, due to late diagnosis among the majority of patients. 
OC is a complex, heterogeneous, and multifactorial disease.  
The relationship between OC and fertility drug use is complicated due to the link between 
infertility and other established reproductive risk factors. We found that fertility drug use does not 
significantly impact OC risk among the majority of women when accounting for confounding 
factors. However, we observed increased OC risk among women who despite fertility drug use 
remained nulligravid. 
Improved understanding of symptom presentation among OC patients could lead to earlier 
detection. However, the identification of OC-related symptoms is difficult due to their non-specific 
nature. Our second project identified 3 subgroups of OC patients that were defined according to 
the total number of symptoms experienced prior to diagnosis. Interestingly, the number of 
symptoms experienced did not differ significantly between early and late stage cases. 
Conditional disease-free survival (DFS) accounts for elapsed time after remission thereby 
providing more relevant prognostic information than traditional DFS estimates. Results from our 
third project demonstrate that DFS estimates improve dramatically over time and that conditional 
DFS provides more relevant and accurate information to patients who have already survived a 
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period of remission. Characteristics that are predictive of DFS at time of remission, such as stage 
and age, lose significance as the period of remission increases. 
The research presented in this dissertation is of public health significance because it 
contributes to what is known about the risk, diagnosis, and prognosis of OC. Enhanced knowledge 
of OC risk factors may improve the identification of women at increased risk of OC and contribute 
to our understanding of OC etiology. The characterization of symptom presentation among OC 
patients prior to diagnosis may assist the development of a screening tool that is able to identify 
women with earlier stage disease. Furthermore, more accurate methods to estimate the risk of 
recurrence among OC survivors has the potential to facilitate personalized follow-up care that is 
cost effective and improves cancer outcomes.  
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1.0  INTRODUCTION 
1.1 INCIDENCE AND MORTALITY 
Ovarian cancer (OC) is the 8th
 
most common cancer among women worldwide. Based on 
GLOBOCAN estimates, there were 225,500 new OC cases and 140,200 deaths attributed to OC 
globally in 2008. Incidence rates for OC are higher in developed countries compared to less 
developed countries with age-standardized rates per 100,000 of 9.4 and 5.0, respectively.
 
It is 
likely that as developing countries progress, OC rates will begin to rise and mirror the higher rates 
currently found in more developed countries.1 Within the United States, it is estimated that there 
will be 22,240 new cases of OC in 2013.2 There are significant differences in OC rates between 
racial and ethnic groups in the United States.3,4 Caucasian women have the highest risk of OC, 
with an age-adjusted incidence rate of 13.3 per 100,000 women during the 20. Age-adjusted rates 
for the same time period (2006-2010) for African Americans, Asian/Pacific Islanders, American 
Indian/Alaska Natives were 9.7, 9.4, 10.7, and 11.3 per 100,000 women, respectively.5 
OC accounts for only 3% of cancers among women in the United States; however, it is the 
fifth most common cause of cancer death among women in this country.2
 
Figure 1 presents overall 
5-year relative survival rates for all cancer sites and the 5 most common causes of cancer death 
among women between 1975 and 2004. OC has a lower 5-year relative survival rate than all cancer 
sites among women and lower survival rates than the other most common causes of cancer death 
2 
among women, with the exception of lung/bronchus cancer. Based on Surveillance Epidemiology 
and End Results (SEER) data from 2002-2008, the overall 5-year relative survival between 2002 
and 2008 was 43.7%. The majority of ovarian cancer cases are diagnosed once their disease has 
progressed to advanced stages (Figure 2). Cases diagnosed when disease is confined to the primary 
site have a 5-year relative survival of 91.5%. However, survival rates decrease drastically among 
cases whose disease has metastasized to regional and distant sites; 5- year relative survival rates 
for these cases are 71.9% and 26.9%, respectively.5 
Figure 1. 5-year relative survival rates for all cancer sites and the 5 cancer sites responsible 
for the most cancer deaths among women, according to year of diagnosis 
3 
Figure 2. Stage distribution of ovarian cancer cases diagnosed between 2000-2010 
1.2 PATHOLOGY 
Ovarian tumors are classified according to the tissue in which they originated. The majority of 
ovarian tumors are epithelial in nature, arising from the epithelial surface of the ovary, and account 
for about 90% of ovarian malignancies, while 6% of cases originate in the stromal-cord and 3% of 
ovarian cancers originate in germ cells.6 All epithelial subtypes are also classified as either invasive 
or borderline. Borderline tumors account for 10-15% of epithelial ovarian tumors and are 
characterized by their lack of invasive implants in the underlying stroma.7 These low malignant 
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potential tumors have a more favorable prognosis than invasive tumors, with survival rates of 99%, 
98%, 96%, and 77% for stages I, II, III, and IV, respectively.8 
Ovarian tumors are further classified according to histologic subtype: serous, mucinous, 
endometrioid, clear cell, transitional (Brenner), and mixed histologies.9
 
The most common of these 
histologic subtypes is serous, which accounts for approximately 52% of all ovarian tumors. 
Mucinous, endometrioid, clear cell, transitional, and mixed histologies each account for 
approximately 11%, 19%, 7%, <1%, and 4%, respectively.9 Due to the differing morphologic, 
molecular, and clinical characteristics of histologic subtypes, ovarian tumors are categorized as 
being either type I or type II. Type I tumors include low-grade and borderline serous tumors, low-
grade endometrioid, mucinous, and clear-cell tumors while type II tumors include high-grade 
serous, high-grade endometrioid, mixed mesodermal, carcinosarcomas, and undifferentiated 
tumors. Characteristics of type I and type II tumors vary greatly. Type I tumors more often present 
during earlier stages of disease, resist standard chemotherapy regimens but may be more 
responsive to hormone therapy. Type II tumors are more prevalent and are usually diagnosed at 
stage III/IV, are more aggressive, and typically respond well to chemotherapy but poorly to 
hormone-based treatments.10,11 This suggests that the subtypes of OC have different etiologies and 
that treatments should be tailored according to the subtypes’ molecular features.12,13
 
It should be 
noted that tumors arising from the fallopian tubes and peritoneum share many molecular and 
clinical characteristics with OC and are often characterized as OC.14  
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1.3 RISK FACTORS 
The causes of OC remain poorly understood, however, epidemiologic studies have successfully 
identified numerous demographic, reproductive, and lifestyle factors associated with OC risk. OC 
risk is strongly associated with age; most cases are diagnosed after menopause and the median age 
at diagnosis is 63 years old.
5 
Race has also been identified as a risk factor, with Caucasian women 
having the greatest risk of OC. The factors that contribute to the reduced risk observed among 
other racial groups are unknown. Research has shown that protective risk factors established 
among Caucasian women are also protective among African-American women but that the 
difference in OC risk may be due in part to the disproportionate frequencies of risk factors between 
these racial groups.3,15 Higher rates of OC risk among Caucasian women may also be due in part 
to the higher rate of BRCA1 and BRCA2 mutations among Caucasians.16 However it is important 
to note that the proportion of OC cases with a positive family history of OC is relatively small.  
Hereditary OC accounts for approximately 10% of all OC cases and includes breast-OC 
syndrome and hereditary non-polyposis colorectal cancer (HNPCC), or Lynch II, syndrome. 
Breast-ovarian cancer syndrome is responsible for 90% of hereditary cancers and is associated 
with germ-line mutations in the BRCA1 and BRCA2 tumor suppressor genes.6 The lifetime risk 
of developing OC is 30-60% among BRCA1 mutation carriers and 15- 30% among BRCA2 
mutation carriers.13,17,18 OC patients that are also BRCA mutation carriers tend to be younger than 
non-hereditary OC patients and they often respond better to treatment with longer survival.19,20 
Patients with HNPCC carry a germ-line mutation in the DNA mismatch repair (MMR) genes, 
usually hMLH1 and hMSH2. HNPCC is associated with an 80% increased risk of colorectal cancer 
and women with HNPCC are 12% more likely to develop OC during their lifetime compared to 
6 
women without the syndrome. However, the percentage of OC patients that have germ-line 
mutations in the HNPCC genes is small (<1%).21 Similar to OC patients with BRCA mutations, 
women affected by HNPCC who develop OC tend to be younger; they are also generally diagnosed 
at an earlier stage compared to OC patients in the general population.22,23
 
In addition, OC patients 
with HNPCC are more likely to have non-serous ovarian tumors.23 Studies assessing whether OC 
patients with HNPCC have improved survival compared to patients with sporadic OC have been 
inconclusive.24,25 
Several reproductive factors have been identified as being protective of OC. Parity has 
consistently been linked to the risk of OC, with the protective effect increasing with each live birth. 
In line with this, nulliparous women are at a greater risk of developing OC compared to women 
with at least one live birth. 26-29 Breastfeeding has also been established as a protective factor 
against OC. Women who have ever breastfed have a reduced risk of developing OC and a dose-
response relationship has been observed for the duration of time spent breastfeeding.30-33 Tubal 
ligation is also associated with a decreased risk of OC and several theories have been proposed to 
explain the mechanism by which tubal ligation reduces the risk of OC 34-36. The first of which 
hypothesizes that tubal ligation prevents the ascent of potential carcinogenic endometrial and 
fallopian tube epithelial cells to the ovaries.37 A second hypothesis states that the surgery creates 
a mechanical barrier that prevents potential carcinogens associated with OC, such as talc, from 
reaching the ovaries via the genital tract.6,38-40 Studies assessing the relationship between fertility 
drug use and OC risk have provided conflicting results. Early studies, including a study by 
Whittemore and colleagues found that women who used fertility drugs were more likely to develop 
OC.26,41,42 Subsequent studies have suggested that there may be an increased risk of OC associated 
with fertility drug use among nulliparous women.43,44 However, other studies have not observed 
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any association between OC and fertility drug use.45-48 Hormonal factors linked to OC include oral 
contraceptive use49-52 and hormone replacement therapy (HRT).53,54 Oral contraceptive use has 
consistently been shown to decrease the risk of OC; however there is some controversy regarding 
the impact that HRT has on OC risk. 55-58 
Several theories have been proposed to explain the mechanisms by which hormonal and 
reproductive factors affect OC risk. The incessant ovulation hypothesis theorizes that the repeated 
damage and subsequent repair cycles that occur during ovulation on the epithelial surface of the 
ovary contributes to DNA damage and increases the risk of developing OC.59-62
 
This hypothesis is 
consistent with reduced risk associated with parity, breast-feeding, and oral contraceptive use. The 
gonadotropin hypothesis postulates that exposure to high levels of circulating pituitary 
gonadotropins, which causes increased estrogen stimulation of the ovarian surface epithelium, 
plays a role in the development of OC.63,64 The hypothesis is supported by the decreased risk 
associated with parity and oral contraceptives but is inconsistent with regards to the decreased risk 
linked to breastfeeding, which increases gonadotropins, and HRT, which reduces gonadotropin 
levels.6
 
The pregnancy clearance hypothesis theorizes that the increased levels of progesterone 
during pregnancy results in the clearance of premalignant and malignantly transformed cells from 
the ovaries.6,65
 
This hypothesis is also supported by the observed risk reduction associated with 
parity. Inflammation has also been proposed as a potential mechanism by which factors affect OC 
risk. The inflammation hypothesis proposes that local inflammation and inflammatory cytokines 
damage the epithelial surface of the ovary; ovulation, talc use, and endometriosis are all associated 
with inflammation and increased risk of OC.6,66
 
Despite the different hypotheses of the biological 
mechanisms involved in ovarian carcinogenesis, the process itself remains poorly understood.  
 
8 
However, the identification of numerous risk factors has established that OC is multifactorial and 
complex in etiology. 
Research regarding the impact of lifestyle factors on OC risk has been inconsistent.6,67 
Several studies have found an increased risk associated with obesity,68-70
 
while others have found 
no association.71,72
 
A recent pooled analysis of studies participating in the Ovarian Cancer 
Association Consortium (OCAC) analyzed the risk of OC associated with body mass index (BMI) 
at three different time points: recent BMI, maximum BMI and early adulthood BMI. Olsen and 
colleagues observed increased risks of borderline and invasive OC at all three time points; 
however, they only observed this association among the less common non-serous and low-grade 
serous subtypes of ovarian tumors.73 The relationship between hormone levels and obesity has 
been proposed as the mechanism by which obesity affects the risk of OC. Specifically, obesity 
affects hormone levels by: increased conversion of androgens to estrogens in adipose tissue, 
increased insulin resistance that results in hyperinsulinemia that subsequently stimulates androgen 
production, increased free estradiol levels due to reduced hormone-binding globulin capacity, and 
hyperstimulation of the adrenal gland. The impact of lifestyle factors including alcohol use33,74,75 
and smoking on OC risk has been similarly inconsistent.33,76,77  
1.4 DIAGNOSIS, TREATMENT, AND SURVIVAL 
OC has traditionally been thought of as a “silent killer”; however, a 2000 study by Goff and 
colleagues provided evidence that the majority of women experience more than one symptom an 
average of 3 to 6 months before their diagnosis. Importantly, they observed that 88% of the women 
diagnosed with early stage disease experienced the same symptoms that women with late stage 
9 
disease reported. The most commonly reported symptoms in their study were: increased abdominal 
size, bloating, fatigue, abdominal pain, and indigestion.78 Interestingly, before they were diagnosed 
with OC, women reported that they were initially diagnosed with irritable bowl syndrome (15%), 
stress (12%), gastritis (9%), or were diagnosed with another condition (47%), and 13% reported 
that they were told nothing was wrong with them. Goff et al reported that patients not recognizing 
that their symptoms were indicative of a serious illness and the misdiagnosis by clinicians both 
contributed to delays in their OC diagnosis.78 Due to these factors, patients are typically diagnosed 
once their disease has progressed to advanced stages. 
Usually, initial diagnostic findings include a palpable abdominal mass. Transvaginal 
ultrasonography (TVU) is then performed to visualize the mass and if ascites are present, 
paracentesis may be done to determine whether the ascitic fluid contains malignant cells. Cancer-
antigen 125 (CA-125) is often collected prior to primary surgery in order to determine the 
probability of a primary ovarian tumor; however, CA-125 can be elevated due to non-malignant 
conditions, such as endometriosis and uterine fibroids.79,80, and alone is not an accurate diagnostic 
measurement. Unless patients are poor candidates for surgery, an exploratory laparotomy is 
performed for diagnostic confirmation, cytoreduction, and staging. 81 The most commonly used 
staging system for OC is the Féderation Internationale de Gynécologie et d’Obstétrique (FIGO) 
system, which is presented in Table 1.82  
Patients with low risk of recurrence generally do not require adjuvant chemotherapy. This 
group includes cases diagnosed with borderline disease or stage Ia, grade 1 disease. Depending on 
the perceived risk of recurrence, women with stage Ia, grade 2, or stage Ib grade1/2 may or may 
not receive adjuvant chemotherapy. The majority of patients are diagnosed with advanced disease 
and the current standard of care for these patients is adjuvant taxane and platinum-based 
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chemotherapy, which most commonly includes Taxol and Carboplatin. The majority of OC 
patients achieve clinical remission upon the completion of primary treatment. 83,84 Unfortunately, 
a large proportion of these women will ultimately develop recurrent disease.85-88 The overall 
average 5-year relative survival rate is 44.2% among OC patients.5 The most significant predictor 
of survival is stage; however, many other patient characteristics impact prognosis. Numerous 
studies have shown that optimal debulking (i.e., residual disease < 1 cm) is a significant predictor 
of survival and cases that are sub-optimally debulked have a poorer prognosis.89-92 Other factors 
associated with prognosis include age,90,93,94 tumor grade,90,92,95 and histologic subtype.89,90,94-96 
Upon completion of primary adjuvant chemotherapy, surveillance for recurrent disease is 
initiated. The European Society of Medical Oncology (ESMO) recommends physical 
examinations every 3 months for 2 years after remission is achieved, every 4 months during the 
third year, and every 6 months beginning in the fourth year of surveillance care. They also 
recommend that CA-125 levels are measured at each visit while imaging scans are recommended 
only if there is a rise in CA-125 levels or there is clinical evidence of recurrent disease.97 However, 
there is controversy regarding whether these surveillance recommendations are able to 
meaningfully improve survival among OC patients.98-101 Several studies have reported that 
physical examinations have a limited impact on detecting recurrent disease and that the majority 
of cases who have recurrent disease detectable by physical exam also present with symptoms or 
elevated CA-125 levels.102,103 A recent, randomized trial assessed the effectiveness of initiating 
recurrent treatment based on rising levels of CA-125 alone compared to initiating treatment only 
when there was clinical evidence of recurrent disease. Rustin and colleagues observed no survival 
benefit among cases whose treatment was initiated based on CA-125 levels alone; in fact, they 
observed an earlier decline in quality of life among these patients.104 Although the use of CA-125 
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levels for the early detection of recurrent disease has not improved OC survival, the majority of 
patients believe routine CA-125 testing was the most important factor in predicting cancer 
survival.105 These results suggest that there is a need for improved clinician-patient communication 
regarding the goals and efficacy of surveillance care. Improved measures of prognosis, particularly 
the risk of recurrence, are needed to aid clinicians and OC patients in making informed decisions 
regarding their follow-up care. 
Table 1. Féderation Internationale de Gynécologie et d’Obstétrique (FIGO) staging 
system for cancer of the ovary 
1.5 SCREENING METHODS 
To date, efforts to develop screening methods to detect OC during the early stages of disease 
development have not been effective. Given the significantly improved prognosis for patients 
1. Stage Characteristics 
I Growth limited to the ovaries. 
Ia Growth limited to one ovary; no ascites present containing malignant cells. No tumor on the external surface; capsule 
intact. 
Ib Growth limited to both ovaries; no ascites present containing malignant cells. No tumor on the external surfaces; 
capsules intact. 
Ic Tumor either stage Ia or Ib, but with tumor on surface of one or both ovaries, or with capsule ruptured, or with ascites 
present containing malignant cells, or with positive peritoneal washings. 
II Growth involving one or both ovaries with pelvic extension. 
IIa Extension and/or metastases to the uterus and/or tubes. 
IIb Extension to other pelvic tissues. 
IIc Tumor either stage IIa or IIb, but with tumor on surface of one or both ovaries, or with capsule(s) ruptured, or with 
ascites present containing malignant cells, or with positive peritoneal washings. 
III Tumor involving one or both ovaries with histologically confirmed peritoneal implants outside the pelvis and/or 
positive regional lymph nodes. Superficial liver metastases equals stage III. Tumor is limited to the true pelvis, but 
with histologically proven malignant extension to small bowel or omentum. 
IIIa Tumor grossly limited to the true pelvis, with negative nodes, but with histologically confirmed microscopic seeding 
of abdominal peritoneal surfaces, or histologic proven extension to small bowel or mesentery. 
IIIb Tumor of one or both ovaries with histologically confirmed implants, peritoneal metastasis of abdominal peritoneal 
surfaces, none exceeding 2 cm in diameter; nodes are negative. 
IIIc Peritoneal metastasis beyond the pelvis >2 cm in diameter and/or positive regional lymph nodes. 
IV Growth involving one or both ovaries with distant metastases. If pleural effusion is present, there must be positive 
cytology to allot a case to stage IV. Parenchymal liver metastasis equals stage IV. 
Adapted from: Oncology FCoG. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. 
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. Apr 
2009;105(1):3-4. 
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diagnosed when disease is confined to the ovaries, earlier detection of OC would likely result in 
significantly improved survival rates. There is currently no standard screening method for the 
detection of OC. CA-125 and TVU have been proposed as a potential screening method but based 
on results from screening trials the protocol has not proven to be effective in detecting early stage 
disease with acceptable false-positive rates.106,107 
In an effort to utilize symptoms experienced by OC patients to predict the presence of 
cancer, several studies have aimed to develop a symptom-based screening tool.108,109 Subsequent 
studies have shown that the use of a symptom index may improve the sensitivity and specificity 
of OC screening when used in combination with diagnostic biomarkers such as CA-125,110 and 
has the potential to improve discrimination between malignant and benign tumors when used with 
transvaginal sonography.111 These results indicate that evaluating symptoms could be useful for 
the identification of women who are at increased risk of having OC and should be referred for 
further screening. However, using an approximation of the Goff et a. OC symptoms index,108 
Rossing et al determined that the use of such a symptoms index in the general population would 
likely have a low positive predictive value and would result in unnecessary medical evaluations 
for women without OC.112 Screening tools utilizing OC symptoms are promising; however, 
improved methods to distinguish between healthy women and women at high risk of having OC 
is needed in order to avoid sending a large number of women for ultimately unnecessary testing.  
1.6 SPECIFIC AIMS 
OC represents a significant public health challenge due to its complex and poorly understood 
etiology, the lack of effective screening methods, and poor survival rates. The goal of this research 
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is to address each of these aspects through the following specific aims: 1) determine whether 
fertility drug use significantly impacts OC risk when accounting for established OC risk factors; 
2) characterize subgroups of OC cases that experience similar symptomatology prior to diagnosis 
and identify the factors that predict membership to these groups; and, 3) assess conditional disease-
free survival among OC cases and identify the prognostic factors that impact survival. 
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2.1 ABSTRACT  
Background: Previous studies examining associations between use of fertility drugs and ovarian 
cancer (OC) risk have provided conflicting results. We used data from a large case-control study 
to determine whether fertility drug use significantly impacts OC risk when taking into account 
parity, gravidity, and cause of infertility. 
Methods: Data from the Hormones and Ovarian Cancer Prediction (HOPE) study were used (902 
cases, 1802 controls). Medical and reproductive histories were collected via in-person interviews. 
Logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI). 
Models were adjusted for age, race, education, age at menarche, parity, oral contraceptive use, 
breastfeeding, talc use, tubal ligation, and family history of breast/ovarian cancer. 
Results: Ever use of fertility drugs was not significantly associated with OC within the total HOPE 
population (OR: 0.93, 95%CI: 0.65–1.35) or among women who reported seeking medical 
attention for infertility (OR: 0.87, 95%CI 0.54-1.40). We did observe a statistically significant 
increased risk of OC for ever use of fertility drugs among women who, despite seeking medical 
attention for problems getting pregnant, remained nulligravid (OR: 3.13, 95%CI 1.01-9.67).  
Conclusions: These results provide further evidence that fertility drug use does not significantly 
contribute to OC risk among the majority of women; however, women who despite infertility 
evaluation and fertility drug use remain nulligravid, may have an elevated risk for OC. 
Impact: Our results suggest that fertility drug use does not significantly contribute to overall risk 
of OC when adjusting for known confounding factors. 
 
 
2.2 INTRODUCTION 
Ovarian cancer (OC) is multifactorial and complex in etiology. Lifestyle factors shown to increase 
the risk of OC include low parity,27-29,113 late onset of menopause114,115 and perineal talc use.38-40 
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Oral contraceptive use,49-52 breastfeeding30-32 and tubal ligation34-36 have been shown to have a 
protective effect on OC risk. Several theories have been proposed to explain the mechanisms by 
which these factors affect risk of OC. The incessant ovulation hypothesis theorizes that the 
repeated damage and subsequent repair cycles that occur during ovulation on the epithelial surface 
of the ovary contributes to DNA damage and increases the risk of developing OC.59-62 The 
gonadotropin hypothesis postulates that exposure to high levels of circulating pituitary 
gonadotropins, which stimulates the ovarian surface epithelium, plays a role in the development 
of OC.63,64 Both of these theories suggest that the use of fertility drugs, which often contain 
gonadotropins and stimulate ovulation, may increase the risk of OC.  
Fertility drug use has increased markedly in the U.S.116 Based on data from the 2002 
National Survey of Family Growth, 12% of the 61.6 million U.S. women between the ages of 16 
and 44 sought infertility services. The use of infertility services was more common among older 
women, women with higher incomes, and women who were childless.117 The utilization of fertility 
drugs and other infertility services is expected to continue to rise as the percentage of women who 
postpone attempts to become pregnant until after the age of 35 increases. Stephen et al projected 
that the number of infertile women will increase to between 5.4-7.7 million in 2025.118 Despite the 
growing number of women seeking fertility treatment, the effects of fertility drug use on OC risk 
remain uncertain. Several early studies reported an association between exposure to fertility drugs 
and the development of OC, which spurred concern regarding the safety of these drugs.26,41,42 
Subsequent studies did not provide evidence of an increased risk of OC with the use of fertility 
drugs.43,45,47,48,119,120 However, concern regarding fertility drug use remains after other studies 
reported that women who were exposed to fertility drugs for more than 12 cycles were at an 
increased risk of OC.121,122 Nulliparous women who failed to conceive after treatment have also 
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been reported to have an increased risk OC.26,45 Finally, several studies have shown that fertility 
drug use may increase the risk of borderline ovarian tumors.41,42,44,46,123,124  
The conflicting results from previous studies might be due to the generally small sample 
sizes and/or inability to control for important reproductive factors known to influence OC risk. 
Establishing the relationship between fertility drug use and OC risk is complicated by the fact that 
infertility itself increases the risk of OC.52,125-127 It is also of particular importance to account for 
parity because the frequency of nulliparity is high among infertile women and nulliparity has been 
established as an important OC risk factor.63,128,129 The increasing use of fertility drugs necessitates 
the separation of the effects of underlying infertility and other confounding factors from those of 
fertility drug use. Ours is one of the largest case-control studies of OC conducted to date. Our 
objective was to contribute to the debate regarding whether fertility drug use significantly impacts 
OC risk when taking into account parity, gravidity, and cause of infertility.  
2.3 MATERIAL AND METHODS 
2.3.1 Study population and data collection 
We used data from the Hormones and Ovarian Cancer Prediction (HOPE) study, a population-
based case-control study of OC described in detail elsewhere.50,130 Briefly, subjects were residents 
of a contiguous region comprising Western Pennsylvania, Eastern Ohio, and Western New York 
State. All cases were histologically confirmed to have primary epithelial ovarian, peritoneal, or 
fallopian tube cancers diagnosed between 2003 and 2008. Eligible women were at least 25 years 
old and were within 9 months of initial diagnosis at the time of recruitment. A total of 902 cases 
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were enrolled. Controls, N=1802, were frequency matched to cases (~2:1) by 5-year age group 
and telephone area code through random-digit dialing. Women who had undergone a bilateral 
oophorectomy were ineligible. All study participants provided informed consent. The study was 
approved by the University of Pittsburgh Institutional Review Board and by the human subject 
committees at each hospital where cases were identified. 
Trained interviewers collected questionnaire data that included detailed reproductive, 
gynecological, and medical histories as well as information regarding lifestyle and family medical 
history; a reference date of 9 months before the interview date was used for all participants. 
2.3.2 Infertility and fertility drug use 
All study participants were asked if they had ever sought medical attention for problems becoming 
pregnant. Women who responded with “yes” to this question were asked whether their partner was 
tested, they were personally tested, they were both tested, or if neither of them were tested for 
infertility. They were also presented with a list of infertility causes and asked whether each was 
found to be a probable cause for their problems becoming pregnant. Women were able to respond 
“yes,” “no,” or “don’t know” to whether they were diagnosed with a problem involving: partner’s 
sperm, their ovaries, ovulation, their fallopian tubes, their cervix, cervical mucous, their uterus, 
scarring of the uterus, menstruation, endometriosis, or some other problem. For the current 
analyses, we collapsed the cervix and cervical mucous variables into one cervical problem 
variable. Similarly, we combined the variables for uterus problems and scarring of the uterus. We 
chose to collapse these variables because the mechanism affecting infertility is similar for both 
cervical variables as well as both uterine variables. Combining similar causes of infertility resulted 
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in a greater number of exposed women and increased our power to determine whether uterine or 
cervical causes of infertility were significantly associated with OC risk. 
All study participants were asked if they had ever used fertility drugs. Women who 
responded with “yes” to this question were asked the name of the fertility drugs used. The majority 
of women used clomiphene citrate, which we defined as one group of fertility drugs 
(“clomiphene”). We pooled follicle stimulating hormone (FSH), human chorionic gonadotropin 
(hCG), gonadotropin-releasing hormone (GnRH), urofollitropin, and human menopausal 
gonadotropin (hMG) drugs into one group of fertility drugs, “gonadotropins”, because they utilize 
the same method of stimulating ovulation. We also created a group for women who had used a 
combination of gonadotropins and clomiphene citrate (“clomiphene + gonadotropins”). Finally, 
we grouped together any other fertility drugs, such as progesterone and unknown hormone pills, 
into an “other” fertility drug group (“other fertility drug”). Women who reported taking fertility 
drugs were also asked how many months they took each fertility drug. This information was 
collected for the first four periods of fertility drug use. We do not have information regarding type 
of fertility drug or the duration of use for fertility drugs used after the first four time periods of 
fertility drug use; however, only 9 women reported using fertility drugs for more than four time 
periods.  
2.3.3 Covariates 
Based on anthropometric data provided by the participants, we calculated body mass index (BMI) 
as weight (kg) at reference date divided by height (m) at reference date squared. Family history of 
ovarian and breast cancers was defined as having at least one reported diagnosis of, respectively, 
ovarian or breast cancer among a first-degree relative. Hormone replacement therapy (HRT) use 
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was defined as the use of hormones for menopause, to treat osteoporosis, or after 
hysterectomy/removal of ovaries; any use of estrogen or estrogen plus progesterone among 
postmenopausal women was also classified as HRT use. Women were classified as 
postmenopausal if they were 55 years or older, reported natural menopause, had used HRT, or 
reported no menstrual periods in the 6 months prior to the reference date. Women were considered 
to be premenopausal if they had never taken HRT and reported having menstrual periods in the 6 
months prior to the reference date, and were younger than 55 years old.131 All participants were 
asked if they had ever been pregnant. Women reporting at least 1 pregnancy were subsequently 
asked to provide information regarding the outcome of the pregnancy and the duration they 
breastfed. This information was repeated for up to four pregnancies. Duration of breastfeeding was 
calculated as the sum of the number of months they breastfed after each of their first four 
pregnancies. Information regarding pregnancy outcomes, and breastfeeding was not available for 
later pregnancies; however, women did report their total number of pregnancies and live births. 
Among women who reported more than four pregnancies, we calculated their average length of 
breastfeeding for their first four pregnancies, multiplied this average by the number of additional 
pregnancies resulting in live births, and added this to the total months of reported breastfeeding. 
Perineal talc use was defined as ever using dusting powder or deodorizing spray on: the genital or 
rectal areas, on sanitary napkins, on underwear, or on diaphragms or cervical caps.  
2.3.4 Statistical analysis 
Associations between OC risk and demographic and reproductive factors were evaluated using 
logistic regression models. These models were used to calculate odds ratios (OR) and 
corresponding 95% confidence intervals (95% CI), as well as p-trend values for continuous factors. 
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Backward stepwise regression was used to determine which demographic and reproductive 
variables should be included as covariates in the regression models used to evaluate the effect of 
exposure to fertility drugs on OC risk. Age was locked into the stepwise model as a continuous 
variable; a p-value criterion of 0.10 was used to identify additional covariates. The following 
variables were evaluated for inclusion: race (white, black, other), education (less than high school 
graduate, high school graduate, post-high school education), site (Pittsburgh, Cleveland, Buffalo), 
BMI (<25, 25-29.99, ≥30), family history (none, first-degree breast, first-degree ovarian, first-
degree ovary and breast), tubal ligation (yes, no, missing), oral contraceptive use (continuous), 
number of live births (0, 1, 2, 3, 4, ≥5), breastfeeding (never, < 6, 6 < 12, ≥ 12 months), age at 
menarche (continuous), menopausal status (premenopausal, postmenopausal), perineal talc use 
(ever, never), and HRT use (ever, never). All models are adjusted for the covariates identified 
through this process with the exception of models in which collinearity occurred between these 
covariates and the variables of interest (indicated with the results). 
Associations between OC risk and ever versus never use of fertility drugs and also duration 
of use, which was evaluated as a continuous variable and as a categorical variable (never, < 6 
months, ≥ 6 months), were evaluated among the total HOPE population and separately among 
women who reported seeking medical attention for infertility. We chose 6 months as the cutoff for 
duration of use because this was the median duration of fertility drug use among all women who 
had taken fertility drugs and using this grouping provided adequate sample size for each group 
when stratifying for parity and gravidity. Among women who reported seeking medical attention 
for infertility, we additionally evaluated associations between OC risk and year medical attention 
was sought, who was tested, and underlying cause of infertility using unconditional logistic 
regression. We also determined whether the relationship between fertility drug use and OC risk 
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was modified by year medical attention was sought, age at which medical attention for infertility 
was sought, cause of infertility, and person tested for infertility problems by creating interaction 
terms between fertility drug use and these variables and including them in the adjusted model. 
Finally, we evaluated whether use of specific types of fertility drugs (clomiphene, gonadotropins, 
clomiphene + gonadotropins, other fertility drugs) was associated with OC risk. These analyses 
were repeated separately for invasive and borderline ovarian tumors; analyses were also repeated 
using all cases and controls within the HOPE study population. 
To examine the impact of parity and gravidity on the association between fertility drug use 
and OC risk, we evaluated ever compared to never use of fertility drugs while stratifying by the 
following groups of women: parous, nulliparous-gravid, and nulligravid. These analyses were 
conducted among women who reported seeking medical attention for infertility and repeated using 
the total HOPE study population. 
All significance tests were two-sided; P values <0.05 were considered statistically 
significant. All analyses were conducted using Stata version 12.1.132  
2.4 RESULTS 
Demographic and reproductive characteristics of the HOPE study population are presented in 
Table 2. Compared to Caucasians, African Americans had a significantly increased risk of OC. 
High-school graduates and women with post-high school education had a significantly decreased 
risk of OC compared to women with less than a high school education. The following variables 
were also significantly associated with OC risk: age at menarche, oral contraceptive use, parity, 
gravidity, duration of breastfeeding, perineal talc use, and tubal ligation. Seeking medical attention 
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for infertility was not significantly associated with OC risk (Table 3). Backward stepwise 
regression yielded a model that included age, race, education, age at menarche, oral contraceptive 
use, parity, duration of breastfeeding, perineal talc use, and tubal ligation. First-degree family 
history of breast/ovarian cancers was associated with a p-value of 0.14 using this method but was 
nevertheless included in the model because of its known association with OC risk.  
Table 3 provides medical information for the 445 women who reported seeking medical 
attention for infertility. No statistically significant association with OC was observed for age at 
which women sought medical attention, year medical attention was initially sought or with person 
tested for infertility problems. None of the causes of infertility were significantly associated with 
OC risk; however, borderline significant associations were observed for ovulation problems and 
menstrual problems. Among the 47 women who reported ovulation problems, 11 had also reported 
an issue with their menstrual cycles.  
Use of fertility drugs was reported by 148 (33%) of the women seeking medical attention 
for infertility (Table 3). The majority used fertility drugs for less than 12 months (66.7%); mean 
duration was 11.4 months (range: 1-134 months). Ever use of fertility drugs was not significantly 
associated with OC risk (Table 3) and remained non-significant after additional adjustment for 
cause of infertility (OR: 0.66, 95%CI: 0.36-1.22), age medical attention was sought (OR: 0.86, 
95%CI: 0.53-1.40), year attention was sought (OR: 0.90, 95%CI: 0.58-1.38), and who was tested 
for infertility problems (no one tested or partner-only tested compared to self tested or partner and 
self tested, OR: 0.90, 95%CI: 0.54-1.49) (not in table). No significant interactions between fertility 
drug use and these variables were observed (data not shown). Similar results were observed for 
duration of fertility drug use (Table 3 and data not shown). Regarding specific types of fertility 
drugs, the majority of women who ever used fertility drugs reported using only clomiphene citrate 
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(56.1%). None of the drugs evaluated were significantly associated with OC risk when looking at 
ever compared to never use (Table 3) or duration of use (data not shown). Analyses were repeated 
excluding the 12 cases and controls that reported using unknown or other fertility drugs and the 
results were unchanged. Additionally, no significant associations between ever use of fertility 
drugs and OC risk were observed when separately assessing borderline (OR: 0.96, 95%CI: 0.31-
2.94; adjusted for age, duration of oral contraceptive use, talc, and age at menarche) and invasive 
tumors (OR: 0.85, 95%CI: 0.52-1.39; adjusted for all covariates identified by stepwise regression). 
Among all 2704 HOPE participants, 152 (5.6%) women reported ever using fertility drugs, 
this included the 148 women who reported seeking medical attention for infertility and 4 women 
who had used fertility drugs but had never sought medical attention for fertility issues. All 4 of 
these latter women were controls; 2 reported taking clomiphene only and 2 reported taking 
gonadotropins only. Data regarding why these four women reported taking fertility drugs without 
ever seeking medical attention for infertility were not collected. Ever use of fertility drugs was not 
significantly associated with OC risk in the total HOPE population (OR: 0.93, 95%CI: 0.65-1.35), 
nor was duration of use (never compared to <6 months of use, OR: 1.05, 95%CI: 0.61-1.80; never 
compared to ≥ 6 months of use, OR: 0.82, 95%CI: 0.50-1.34), adjusting for age, race, education, 
tubal ligation, age of menarche, duration of oral contraceptive use, number of live births, duration 
of breastfeeding, perineal talc use, and family history. Adjusting for the same covariates, no 
significant associations between OC risk and ever use of fertility drugs were observed when 
separately evaluating borderline (OR: 0.64, 95%CI: 0.26-1.55) and invasive tumors (OR: 1.02, 
95%CI: 0.69-1.50). 
Table 4 presents results of the evaluation of associations between fertility drug use and OC 
risk stratified by parity and gravidity. Among those seeking medical attention for infertility, 
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nulligravid women who used fertility drugs were significantly more likely to develop OC than 
nulligravid women who had never used fertility drugs. However, fertility drug use among parous 
and nulliparous-gravid women was not significantly associated with OC risk among this group of 
women. Within the total HOPE study population, the association between OC risk and ever use of 
fertility drugs was non-significant among parous and nulliparous-gravid women. OC risk was 
elevated among nulligravid fertility drug users; however, this was not significant (Table 4).  
2.5 DISCUSSION 
In this large case-control study, we evaluated whether fertility drug use significantly affects OC 
risk when taking into account, parity, gravidity, and cause of infertility. Consistent with results 
from previous studies, oral contraceptive use, breastfeeding, and tubal ligation significantly 
decreased OC risk in our study population while nulliparity, and perineal talc use increased 
risk.34,43,44,63,133 Ever use of fertility drugs was not significantly associated with OC risk within the 
total HOPE population or among women who reported seeking medical attention for infertility. 
Risk did not differ significantly according to duration of use or type of fertility drug. However, we 
did observe a statistically significant increased risk of OC for ever use of fertility drugs among 
women who, despite seeking medical attention for problems getting pregnant, remained 
nulligravid.  
When examining specific causes of infertility among those seeking medical attention for 
infertility, none of the evaluated causes were significantly associated with OC risk. Specifically, 
we observed no significant association between OC and endometriosis even though previous 
studies have reported an increased risk.44,134-136 Endometriosis was also not significantly associated 
26 
with OC risk in the total HOPE population (data not shown). The mechanism by which 
endometriosis may affect OC risk is poorly understood; however, several studies have shown that 
endometriosis-associated tumors are most commonly linked to clear cell and endometrioid tumors 
(55-58).137-140 The small number of women who reported being diagnosed with endometriosis 
among those who sought medical attention for infertility in addition to the homogeneity of tumor 
histologic subtypes among these women may have contributed to the null relationship we observed 
here. Interestingly, we observed a decreased risk of OC among women who reported an ovulation 
problem as their cause of infertility. Although this observation was of borderline significance, it 
suggests that women who ovulate less frequently throughout their lifetime may have a decreased 
risk of OC and provides further evidence for the incessant ovulation theory.  
In a 2004 case-control study, Rossing et al observed that women whose infertility 
manifested past the age of 30 were at increased risk of OC.43 We found no significant association 
between OC risk and the age at which women sought medical attention for infertility in our 
population; however, women who sought help between the ages of 35 and 45 did exhibit a non-
significant increased risk compared to women who sought help before they were 25. Women who 
seek treatment for infertility past the age of 30 have a lower likelihood of success compared to 
women who seek infertility treatments at younger ages141 and OC risk associated with infertility 
among older women may reflect additional risk associated with low parity among these women.  
Although we did not observe any significant associations between fertility drug use and 
OC risk within the total HOPE study population or among the subset of women who reported 
seeking medical attention for infertility, we did observe, similar to previous reports, a statistically 
significant increased risk of OC associated with ever fertility drug use among nulligravid women 
who had infertility problems.26,44,45 This suggests that women who never became pregnant despite 
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efforts to conceive are at uniquely increased risk of OC. This is further supported by the fact that 
we found no significant association between fertility drug use and OC risk among nulliparous 
women who had at least one pregnancy. Although our results are in line with those from previous 
studies, it should be noted that the number of nulligravid women who sought medical attention for 
infertility was relatively small (N=74). Therefore, confirmation of our results by other studies is 
necessary.  
Our finding that fertility drug use does not significantly contribute to OC risk among the 
majority of women is in line with results from other, recent studies.43,44,48,133 Early studies that 
reported an increased risk of OC among fertility drug users included small numbers of OC patients 
exposed to fertility drugs and were unable to adjust for risk factors known to impact OC risk.26,41 
We observed no risk difference between borderline and invasive tumors; these results are in 
agreement with a recent case-control study142 but disagree with several previous 
studies.41,42,44,46,123,124  
The strengths of this study include a large sample size and availability of detailed 
reproductive and medical histories of women included in the study. The ability to stratify and 
adjust for factors linked to OC risk allowed us to disentangle risk associated with these factors 
from risk associated with fertility drug use. A limitation of our study is that we were unable to 
identify women who were infertile but never sought medical attention. This differential 
misclassification may have attenuated the associations between infertility and OC risk. However, 
our ability to analyze associations between fertility drug use and OC risk in a relatively large subset 
of women who had sought medical attention for infertility greatly improved the comparability of 
fertility drug users to non-users. Being able to reduce the study population to only these women 
also limited biases associated with comparing fertility drug users with infertility issues to non-
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fertility drug users with no history of infertility issues. Our study is also limited by its reliance on 
self-reported use of fertility drugs; however, the use of a life calendar during interviews may have 
improved the accuracy of recalling details about fertility drug use. This study includes a greater 
number of OC cases exposed to fertility drugs than previous studies. Despite this, our study had 
limited power when completing stratified analyses for fertility drug use and OC risk, which 
resulted in small subgroups and subsequently wide confidence intervals.  
Our results build upon previous research and provide further evidence that fertility drug 
use does not significantly contribute to overall risk of OC when adjusting for known confounding 
factors. Our observation that fertility drug use was only significantly associated with increased OC 
risk among nulligravid women who had ever sought medical attention for infertility suggests that 
a biological mechanism associated with the inability to conceive may impact OC risk to a greater 
extent than fertility medications do.  
To conclude, these results are reassuring for women and clinicians embarking on fertility 
drug usage in the setting of infertility treatment.  
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2.6 TABLES 
Table 2. Demographic and reproductive characteristics of the total HOPE population 
Cases (902) Controls (1802) OR (95% CI) a p-trend b 
N % N % 
Site 
Buffalo 251 27.8 476 26.4 1.0 (ref.) --- 
Cleveland 294 32.6 628 34.9 0.89 (0.72, 1.09) c 
Pittsburgh 357 39.6 698 38.7 0.97 (0.79, 1.18) c 
Age (in years) 
< 30 13 1.4 24 1.3 1.0 (ref.) 0.01 
30 < 40 47 5.2 108 6.0 0.80 (0.38, 1.71) c 
40 < 50 164 18.2 393 21.8 0.77 (0.38, 1.55) c 
50 < 60 276 30.6 569 31.6 0.90 (0.45, 1.79) c 
60 < 70 211 23.4 403 22.4 0.97 (0.48, 1.94) c 
≥ 70 191 21.2 305 16.9 1.16 (0.57, 2.33) c 
Race 
White 856 94.9 1,758 97.6 1.0 (ref.) --- 
Black 35 3.9 29 1.6 2.48 (1.51, 4.08) c 
Other 11 1.2 15 0.8 1.51 (0.69, 3.29) c 
Education 
Non-high school graduate 83 9.2 82 4.5 1.0 (ref.) --- 
High school graduate 303 33.6 535 29.7 0.59 (0.42, 0.83) d 
Post-high school 516 57.2 1,185 65.8 0.46 (0.33, 0.64) d 
Smoking Status 
Never Smoker 458 50.8 913 50.7 1.0 (ref.) --- 
Former Smoker 286 31.7 545 30.2 1.02 (0.84, 1.22) 
Current Smoker 158 17.5 344 19.1 0.86 (0.69, 1.08) 
Body Mass Index (in kg/m2) e 
< 25 300 33.3 671 37.2 1.0 (ref.) 0.08 
25 - 29.99 267 29.6 528 29.3 1.09 (0.89, 1.33) 
≥30 334 37.0 602 33.4 1.18 (0.97, 1.43) 
Family History (1st degree) 
No 715 79.3 1,491 82.7 1.0 (ref.) --- 
Breast Cancer Only 147 16.3 255 14.2 1.21 (0.96, 1.51) 
Ovarian Cancer Only 32 3.5 44 2.4 1.51 (0.95, 2.42) 
Breast and Ovarian Cancers 8 0.9 12 0.7 1.21 (0.48, 3.00) 
Age at Menarche (in years) 
<12 182 20.2 444 24.6 1.0 (ref.) 0.22 
12 257 28.5 463 25.7 1.38 (1.09, 1.74) 
13 243 26.9 484 26.9 1.26 (0.99, 1.59) 
≥14 220 24.4 411 22.8 1.27 (1.00, 1.62) 
Menopausal Status 
Premenopausal 234 25.9 482 26.8 1.0 (ref.) --- 
Postmenopausal 668 74.1 1,320 73.2 0.80 (0.63, 1.03) 
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Table 2. (Continued) 
 Cases (902) Controls (1802) OR (95%CI) a p-trend b 
 N % N %   
Oral Contraceptive Use ( months) f       
Never 367 40.7 531 29.5 1.0 (ref.) < 0.01 
< 6 96 10.6 161 8.9 0.88 (0.65, 1.18)  
6 < 24 135 15.0 282 15.6 0.69 (0.53, 0.89)  
24 < 60 122 13.5 297 16.5 0.61 (0.47, 0.79)  
60 < 120 123 13.6 299 16.6 0.63 (0.48, 0.82)  
≥ 120 58 6.4 232 12.9 0.37 (0.27, 0.52)  
Hormone Replacement Therapy Use       
Never 543 60.2 1039 57.7 1.0 (ref.) --- 
Ever 359 39.8 763 42.3 0.87 (0.73, 1.03)  
Number of Pregnancies       
0 167 18.5 167 9.3 1.0 (ref.) < 0.01 
1 114 12.6 188 10.4 0.57 (0.41, 0.78)  
2 216 24.0 458 25.4 0.44 (0.33, 0.58)  
3 167 18.5 426 23.6 0.36 (0.27, 0.47)  
4 112 12.4 284 15.8 0.34 (0.25, 0.46)  
≥5 126 14.0 279 15.5 0.34 (0.25, 0.47)  
Number of Live Births       
0 213 23.6 230 12.8 1.0 (ref.) < 0.01 
1 117 13.0 228 12.7 0.51 (0.38, 0.68)  
2 263 29.2 593 32.9 0.45 (0.35, 0.57)  
3 170 18.8 418 23.2 0.39 (0.30, 0.51)  
4 73 8.1 190 10.5 0.32 (0.23, 0.45)  
≥5 66 7.3 143 7.9 0.32 (0.22, 0.47)  
Duration of Breastfeeding (months)       
Never 610 67.6 928 51.5 1.0 (ref.) < 0.01 
< 6 117 13.0 296 16.4 0.60 (0.47, 0.76)  
6 < 12 66 7.3 199 11.0 0.54 (0.40, 0.72)  
≥ 12 109 12.1 379 21.0 0.46 (0.36, 0.59)  
Perineal Talc Use       
No 653 72.4 1426 79.1 1.0 (ref.) --- 
Yes 249 27.6 376 20.9 1.40 (1.16, 1.69)  
Tubal Ligation       
No 666 73.8 1162 64.5 1.0 (ref.)  
Yes 201 22.3 616 34.2 0.55 (0.46, 0.67) --- 
Unknown 35 3.9 24 1.3 2.66 (1.57, 4.53)  
Sought Medical Attention for Infertility       
Never 747 82.8 1512 83.9 1.0 (ref.) --- 
Ever 155 17.2 290 16.1 1.15 (0.93, 1.43)  
a Odds ratios and corresponding confidence intervals are adjusted for age (continuous), race (white, black, other), and education 
(non-high school graduate, high school graduate, post high-school), unless otherwise noted. 
b P-trend values were obtained from logistic regression models by using continuous versions of these factors; all models were 
adjusted for age, race, and education with the exception of age, which was unadjusted. 
c  Unadjusted. 
d  Adjusted for age and race. 
e 1 case and 1 control were missing weight information. 
f 1 case was missing oral contraceptive use information. 
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Table 3. Medical information, infertility causes, and ovarian cancer risk among 
HOPE participants seeking medical attention for infertility (N=445)
Cases (155) Controls (290) OR (95% CI) a 
N % N % 
Year Medical Attention was Sought 
≤1970 55 35.5 97 33.5 1.0 (ref.) 
1970≤1980 39 25.2 76 26.2 1.13 (0.55, 2.31) b 
1980≤1990 31 20.0 74 25.5 0.77 (0.31, 1.91) b 
After 1990 30 19.3 43 14.8 1.09 (0.34, 3.47) b 
Age at Which Medical Attention was Sought (in years) 
< 25 47 30.3 86 29.7 1.0 (ref.) 
25 < 30 52 33.5 110 37.9 0.94 (0.55, 1.61) b 
30 < 35 35 22.6 68 23.4 0.89 (0.48, 1.66) b 
35 < 40 17 11.0 18 6.2 2.00 (0.84, 4.75) b 
≥ 40 4 2.6 8 2.8 0.84 (0.21, 3.37) b 
Fertility Testing Done 
None 20 12.9 50 17.2 1.0 (ref.) 
Partner 12 7.7 17 5.9 1.41 (0.53, 3.75)  
Self  55 35.5 84 29.0 1.32 (0.66, 2.67)  
Both 68 43.9 139 47.9 0.92 (0.47, 1.81)  
Fertility Drug Use 
Never 105 67.7 192 66.2 1.0 (ref.) 
Ever 50 32.3 98 33.8 0.87 (0.54, 1.40) 
Type of Fertility Drug 
Never 105 67.7 192 66.2 1.0 (ref.) 
Clomiphene Only 28 18.1 55 19.0 0.87 (0.49, 1.56)  b 
Gonadotropin Only 7 4.5 20 6.9 0.51 (0.20, 1.32)  b 
Gonadotropin + Clomiphene Only 9 5.8 17 5.8 0.94 (0.37, 2.42)  b 
Other Only c 6 3.9 6 2.1 1.87 (0.53, 6.65)  b 
Duration of Fertility Drug Use (in months) d 
Never 105 67.7 192 66.2 1.0 (ref.) 
< 6 22 14.2 41 14.1 0.92 (0.48, 1.74) b 
≥ 6 27 17.4 57 19.7 0.75 (0.42, 1.34)  b 
Low Sperm Count e 
No 130 83.9 229 79.0 1.0 (ref.) 
Yes 25 16.1 55 19.0 0.68 (0.39, 1.18) b 
Problems with ovaries (cysts) e 
No 141 91.0 264 91.0 1.0 (ref.) 
Yes 14 9.0 21 7.2 1.32 (0.61, 2.84) b 
Ovulation Problems e 
No 144 92.9 248 85.5 1.0 (ref.) 
Yes 11 7.1 36 12.4 0.51 (0.24, 1.09) b 
Tubal Problems e 
No 137 88.4 245 83.5 1.0 (ref.) 
Yes 18 11.6 40 13.8 0.62 (0.33, 1.18) b 
Uterine Problems e 
No 147 94.8 274 94.5 1.0 (ref.) 
Yes 8 5.2 11 3.8 1.04 (0.38, 2.83) b 
Menstrual Problems e 
No 146 94.2 254 87.6 1.0 (ref.) 
Yes 9 5.8 30 10.3 0.48 (0.20, 1.11) b 
Endometriosis e 
No 141 91.0 259 89.3 1.0 (ref.) 
Yes 13 8.4 25 8.6 0.75 (0.35, 1.59) b 
Cervical Problems e 
No 152 98.1 277 95.5 1.0 (ref.) 
Yes 3 1.9 8 2.8 0.53 (0.11, 2.59) b 
Other Diagnosis e 
No 126 81.3 240 82.8 1.0 (ref.) 
Yes 29 18.7 46 15.9 1.56 (0.87, 2.79) b 
a ORs and corresponding 95% CIs are adjusted for age, race, education, tubal ligation, age of menarche, duration of oral contraceptive use, 
number of live births, duration of breastfeeding, perineal talc use, and family history of breast/ovary cancers. 
b Due to collinearity, family history of breast/ovarian cancer was omitted from the adjusted logistic regression model. These ORs and 
corresponding 95% CIs are adjusted for all other variables listed in a.
c Includes the following fertility drugs: roloxifene, danazol, unknown hormone pills, bromocriptine, progesterone, and metformin. 
d Duration of fertility drug use was missing for one case and was therefore not included in the logistic regression model; percentages 
correspond to the entire population of women who sought medical attention for problems getting pregnant. 
e These variables exclude women who responded “don’t know” when asked if they were diagnosed with a particular infertility problem and 
these women were also not included in logistic regression models. Percentages correspond to the entire population of women who sought 
medical attention for problems getting pregnant. 
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Table 4. Ovarian cancer risk according to parity, gravidity, and fertility drug use in total HOPE population and separately 
among HOPE participants that sought medical attention for infertility 
Women Who Sought Medical Attention for Infertility Total HOPE Population 
Parity Gravidity Fertility Drug Use Cases (N=155) 
N (%) 
Controls (N=290) OR (95% CI)   Fertility Drug Use Cases (N=902) Controls (N=1802) OR (95% CI) 
Parous No 80 (51.6) 156 (53.8) 1.0 (ref.) No 666 (73.8) 1493 (82.8) 1.0 (ref.) 
Yes 23 (14.8) 75 (25.9) 0.57 (0.31, 1.05) a Yes 23 (2.6) 79 (4.4) 0.72 (0.44, 1.19) a 
Nulliparous Ever Pregnant No 8 (5.2) 9 (3.1) 1.0 (ref.) No 37 (4.1) 52 (2.9) 1.0 (ref.) 
Yes 9 (5.8) 11 (3.8) 0.47 (0.09, 2.53) b Yes 9 (1.0) 11 (0.6) 0.77 (0.26, 2.25) d  
Nulliparous Never Pregnant No 17 (11.0) 27 (9.3) 1.0 (ref.) No 149 (16.5) 155 (8.6) 1.0 (ref.) 
Yes 18(11.6) 12 (4.1) 3.13 (1.01, 9.67) c Yes 18 (2.0) 12 (0.7) 1.52 (0.68, 3.41) e 
a Adjusted for: age, age of menarche, duration of OC use, perineal talc use, education, family history of breast/ovarian cancers, tubal ligation, race, duration of breastfeeding, and number of live births. 
b Adjusted for: age, age of menarche, duration of OC use, and perineal talc use. 
c Adjusted for: age, age of menarche, duration of OC use, perineal talc use, education, and family history of breast/ovarian cancers. 
d Adjusted for: age, age of menarche, duration of OC use, perineal talc use, education, family history of breast/ovarian cancers, and tubal ligation. 
e Adjusted for: age, age at menarche, duration of  OC use, perineal talc use, education, and tubal ligation. 
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3.1 ABSTRACT  
Background: Ovarian cancer (OC) has traditionally been considered an asymptomatic disease. 
However, recent studies have established that the majority of women experience symptoms prior 
to diagnosis. Improved knowledge of the symptoms associated with OC could lead to earlier 
detection. Unfortunately, identification of OC-related symptoms is hampered due to their non-
specific nature.  
Objectives: To determine whether there are subgroups of OC cases that experience similar 
symptom profiles prior to diagnosis, establish whether these profiles differ according to stage at 
diagnosis, and identify characteristics that predict membership to these subgroups. 
Methods: We examined data from 902 ovarian, peritoneal, and tubal cancer cases enrolled in the 
Hormones and Ovarian Cancer Prediction (HOPE) study. Information regarding symptoms 
experienced prior to diagnosis was collected via in-person interviews. Latent class analysis (LCA) 
was used to identify symptom profiles among study participants. Differences in demographic, 
lifestyle, and disease characteristics between subgroups were evaluated using chi-square tests. 
Results: LCA yielded a model with 3 classes which were primarily characterized by the total 
number of symptoms experienced prior to diagnosis and were labeled: “Low Symptomatology” 
(N=436), “Moderate Symptomatology” (N=397), and “High Symptomatology” (N=69). The 
median number of symptoms reported for each class was 2 (range 0-6), 6 (range 2-12), and 13 
(range 10-20), respectively. LCA completed separately for early (I/II) and late (III/IV) stage cases 
yielded similar results. Among all study participants, class membership was significantly 
associated with study site (P<0.01), age (P <0.01), and oral contraceptive use (P<0.01). Smoking 
status and tumor type were significantly associated with class membership among early stage cases 
only. 
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Conclusion: Using LCA, we identified 3 subgroups of OC cases that were defined by the 
total number of symptoms experienced prior to diagnosis. Interestingly, the number of symptoms 
experienced prior to diagnosis did not significantly differ between early and late stage cases. Our 
data suggests that raising awareness of the seriousness of symptoms experienced in combination 
may result in more women seeking medical attention before their OC progresses to late stage 
disease.  
3.2 INTRODUCTION 
The majority of ovarian cancer (OC) cases are diagnosed with advanced-stage disease and, as a 
result, their prognosis is poor. Women diagnosed with early-stage (I/II) disease have significantly 
higher five-year survival rates than women with advanced-stage disease (III/IV).5 Improved early 
detection strategies could therefore result in higher survival rates.  
OC has traditionally been considered an asymptomatic disease. However, more recent 
studies have provided evidence that a significant proportion of women do experience symptoms 
prior to diagnosis, with many experiencing more than one.78,109,112,143,144 This indicates that 
evaluating symptoms may be useful for identifying women who are at increased risk of having OC 
and should be referred for further screening. Unfortunately, the identification of OC symptoms 
and their use in early detection strategies is complicated due to the non-specific nature of the 
symptoms. As a result, the ability of symptoms to improve current OC screening methods has 
remained limited by the large number of women in the general population that experience OC-
related symptoms but do not have OC. Previous studies have characterized OC symptom 
presentation based on the individual ability of symptoms to predict OC. These studies then created 
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symptom indexes by comparing the predictive values of models that included various 
combinations of these symptoms.108,109 However, results reported by Rossing et al showed that the 
use of such a symptoms index in the general population would likely have a low positive predictive 
value and would result in unnecessary medical evaluations for many women without OC.112 In 
order to develop a symptom-based method that can predict the presence of OC with high sensitivity 
and specificity, there is a strong need to increase knowledge of symptom presentation prior to OC 
diagnosis and identify factors related to symptom presentation that are unique to women with OC. 
We hypothesized that OC cases experience many different symptoms prior to diagnosis 
that can be grouped into unique symptom profiles. We utilized latent class analysis (LCA) to 
identify these profiles. LCA is a model-based, person-centered method that defines and 
characterizes unobservable characteristics derived from individuals’ response patterns to a number 
of categorical items.145-148 We applied LCA to data collected as part of the Hormones and Ovarian 
Cancer Prediction (HOPE) study50,130,149 to determine whether there are subgroups of OC cases 
that experience similar symptom profiles prior to diagnosis. We additionally evaluated whether 
the symptom profiles differed according to stage at diagnosis and whether demographic, lifestyle 
and disease characteristics predicted membership to the subgroups. To our knowledge, this is the 
first study to use LCA to examine the heterogeneity in OC symptoms experienced prior to 
diagnosis.  
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3.3 MATERIAL AND METHODS 
3.3.1 Study population and data collection 
Study participants included in our analyses were all enrolled as part of the HOPE study, a 
population-based case-control study (902 cases and 1802 controls), the details of which are 
described elsewhere. 50,130,149 Information on symptoms was not collected from controls; 
consequently, the current analysis is restricted to HOPE participants enrolled as cases. Cases, 
recruited between 2003 and 2008 from Western Pennsylvania (PA), Eastern Ohio (OH), and 
Western New York State (NY), were women 25 years or older who had been diagnosed with 
primary ovarian, peritoneal or fallopian tube cancers within 9 months prior to recruitment. Trained 
interviewers collected demographic, lifestyle, reproductive and medical history information via 
in-person interviews using life calendars to aid in the recollection of past exposures. A reference 
date of 9 months prior to the interview date was used in an effort to identify only the exposures 
that occurred before women were diagnosed with cancer. Cases were also asked to provide contact 
information for all clinicians from whom they received medical care. Disease characteristics were 
abstracted from surgical records, pathology reports, hospitalization records, oncologist notes and 
CA-125 lab results provided by the cases’ healthcare providers. All study participants provided 
informed consent. The study was approved by the University of Pittsburgh Institutional Review 
Board and by the human subject committees at each hospital where cases were identified and 
enrolled.  
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3.3.2 Demographic and lifestyle characteristics 
Based on anthropometric data provided by the participants, we calculated body mass index (BMI) 
as weight (kg) at reference date divided by height (m) at reference date squared. Study participants 
were considered to be never smokers if they had never smoked cigarettes daily for 6 months or 
more; former smokers if they had ever smoked cigarettes daily for 6 months or more but were not 
smoking daily at the reference date; and, current smokers if they had ever smoked cigarettes daily 
for 6 months or more and were smoking daily at the reference date. Alcohol use was quantified by 
adding the number of wine, beer, and hard liquor drinks consumed per week. Women who 
consumed less than 7 drinks per week were classified as light drinkers, cases who consumed 7-14 
drinks per week as moderate drinkers, and cases who reported drinking more than 14 drinks per 
week as heavy drinkers. Family history of ovarian and breast cancers was defined as having at 
least one reported diagnosis of, respectively, ovarian or breast cancer among a first-degree relative, 
including biological mother, father, sisters, brothers, sons and daughters. Participants were asked 
to provide the duration of each time period that they took oral contraceptives. Based on this 
information, oral contraceptive use was categorized as never used, used for less than 5 years, and 
used for 5 years or longer. Hormone replacement therapy (HRT) use was defined as the use of 
hormones for menopause, to treat osteoporosis, or after hysterectomy/removal of ovaries; any use 
of estrogen or estrogen plus progesterone among postmenopausal women was also classified as 
HRT use. Women were classified as postmenopausal if they were 55 years or older, reported 
natural menopause, had used HRT, or reported no menstrual periods in the 6 months prior to the 
reference date. Women were considered to be premenopausal if they had never taken HRT and 
reported having menstrual periods in the 6 months prior to the reference date, and were younger 
than 55 years old.131  
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3.3.3 Disease characteristics 
Information regarding type of cancer (borderline ovarian, invasive ovarian, fallopian tube, 
peritoneal, or other/unknown), histologic subtype (serous, endometrioid, mucinous, clear cell, 
Brenner, mixed, or other/unknown), grade (borderline tumor, well differentiated, moderately 
differentiated, or poorly differentiated/undifferentiated) and stage at diagnosis was abstracted from 
pathology reports. Women diagnosed with stage I or II OC were classified as having early stage 
disease and women diagnosed with stage III or IV were classified as having late stage disease. Pre-
treatment CA-125 levels were obtained from lab results, oncologist notes, and hospital records. 
Using these sources, pre-treatment CA-125 levels were available for 688 (76.3%) cases. CA-125 
levels were considered within normal range if they were less than 35 U/mL and elevated if they 
were 35 U/mL or greater.  
3.3.4 Ovarian cancer symptoms 
All cases were shown a card that listed 23 symptoms; please see Table 7 for this list. Participants 
were asked to indicate which of these symptoms they had experienced prior to their cancer 
diagnosis, regardless of whether they realized at the time that it were symptoms of their disease. 
For the purpose of the current analysis, women are considered to have had the symptom 
independent of whether or not they suspected, prior to diagnosis, that the symptom was indicative 
of a larger health problem. Women who reported telling a doctor about a specific symptom were 
also asked to provide the date and type of appointment as well as the type of doctor they told.  
41 
3.3.5 Statistical analysis 
Differences in diagnosis-related factors (e.g., primary reason for provider visit that led to 
diagnosis) between participants with early and late stage OC were assessed using chi-square tests. 
For each of the 23 symptoms, we first separately evaluated the associations with OC diagnosis and 
with stage of disease using logistic regression to calculate odds ratios (ORs) and corresponding 
95% confidence intervals (CIs). In these analyses, women who had not experienced the symptom 
being evaluated were used as the reference group. Logistic regression was also used to evaluate 
the associations between both total number of symptoms experienced (0, 1, 2, 3, 4, 5, 6, 7, ≥8 
symptoms) and time elapsed between onset of first symptom and diagnosis (<1, 1<3, 3<6, 6<9, 
9<12, ≥12 months), and OC diagnosis and stage of disease. Linear trend was assessed for these 
two factors as well by including them as continuous variables in logistic regression models. 
LCA was used to identify latent classes among OC cases based on symptoms experienced 
prior to diagnosis.145-148 LCA is a data-driven method and information regarding the number of 
latent classes and the size of each class is not known a priori. To determine the optimal number of 
classes, latent class models were fit using 1, 2, 3, 4, and 5 classes, with the final model chosen by 
comparing the goodness-of-fit with the Bayesian information criteria (BIC), Akaike information 
criteria (AIC), and the Lo-Mendel-Rubin likelihood ratio test (LMR- LRT). Study participants 
were assigned to the class for which they had the highest probability of membership. This process 
was repeated separately for early and late stage cases. Once the optimal LCA model was identified, 
we assessed the associations between class membership and demographic, lifestyle, and disease 
characteristics using chi-square tests among all study participants as well as separately for early 
and late stage cases.  
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LCA was performed using Mplus version 6.12 (Muthén & Muthén, Los Angeles, CA).150 
Stata version 12 was used for all other analyses.132  
3.4 RESULTS 
Selected demographic and disease characteristics of the study population are presented in Table 5. 
The majority of women were older than 55 years, Caucasian, post-menopausal, and had been 
diagnosed with late stage cancer. Diagnosis-related factors (i.e., reason for visit, pre-treatment CA-
25 levels, etc.) are presented in Table 6. Symptoms were the most commonly reported primary 
reason for the provider visit that led to diagnosis and a gynecological oncologist diagnosed the 
majority of women. Both primary reason for visit and healthcare provider differed significantly 
between early and late stage cases: late stage cases more often reported having symptoms, a 
surgery other than hysterectomy, or another problem as the primary reason for the visit that led to 
their diagnosis. Women with late stage disease were also more likely diagnosed by a PCP/general 
practitioner and less likely by an obstetrician/gynecologist. Only 7.4% of the women were actively 
seeking treatment to watch for OC and the majority had an annual gynecological exam within one 
year prior to diagnosis. This did not differ significantly between early and late stage cases. The 
majority of women had elevated pre-treatment CA-125 levels; elevated CA-125 levels were 
significantly more common among late stage cases than early stage cases. 
Only 2.7% of the study participants reported that their physician or gynecologist had ever 
explained the signs and symptoms of OC to them and only 13.0% reported that they were aware 
of the signs and symptoms of OC prior to their diagnosis. However, 93.0% reported experiencing 
at least one symptom prior to their diagnosis, regardless of whether they realized at the time that 
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it was a symptom of their disease (Table 6). In our study population, women with invasive tumors 
were 2.27 times more likely to experience at least one symptom than women with borderline 
tumors (95% CI: 1.19-4.35; not in Table). Among participants with available pre-treatment CA-
125 level information, 77.9% experienced symptoms prior to diagnosis and had an elevated CA-
125 level, 15.3% experienced symptoms prior to diagnosis but their CA-125 levels were not 
elevated, 5.5% had an elevated CA-125 level only, and 1.3% did not experience any symptoms 
prior to diagnosis and had CA-125 levels within normal limits (not in Table). 
Table 7 summarizes results for each of the 23 symptoms listed on the card shown to the 
study participants. The most common symptoms experienced (experienced by ≥30% of the 
women) were bloating, weight gain or loss, and pelvic or abdominal discomfort. Women who 
experienced the following symptoms were significantly more likely to have made the health care 
visit that led to their diagnosis due to symptoms compared to a reason other than symptoms: 
bloating, weight gain or loss, pelvic or abdominal discomfort, ongoing fatigue, abdominal 
swelling, distended abdomen, gas, feeling full, severe pelvic pain, indigestion, heartburn, abnormal 
bleeding, decreased appetite, and hard abdomen. Most symptoms were not associated with tumor 
stage. However, abdominal swelling, distended abdomen, and decreased appetite were 
significantly more common among women diagnosed with late stage disease while abnormal 
bleeding and abdominal mass were significantly more often reported by women with early stage 
disease. 
Table 8 presents data pertaining to the total number of symptoms experienced prior to 
diagnosis and the time elapsed between the onset of the first symptom and the date of diagnosis. 
We observed a significant association between the total number of symptoms (continuous) 
experienced and the likelihood that symptoms were the reason for scheduling the healthcare visit 
44 
that led to diagnosis, compared to all other reasons for scheduling the healthcare visit (P-trend: 
<0.01). The total number of symptoms (continuous) did not impact the likelihood of being 
diagnosed with early versus late stage disease (P-trend: 0.43). Time elapsed between onset of first 
symptom (continuous) and the date of the visit that led to the diagnosis was significantly associated 
with whether symptoms led to the diagnosis (P-trend: <0.01). Overall, the association between 
time elapsed between onset of first symptom (continuous) and stage at diagnosis was not 
significant (P-trend: 0.09). However, participants with late stage disease were more likely to have 
experienced their symptoms less than 3 months before their OC diagnosis compared to early stage 
cases. 
A latent class model with three classes was chosen based on the comparatively low BIC 
value and the significance of the LMR-LRT, in addition to its parsimony and interpretability. 
Figure 3 presents the probabilities of experiencing each symptom according to class. As evidenced 
in Figure 4, the classes were primarily defined by the total number of symptoms experienced rather 
than by specific symptoms experienced. We therefore labeled classes 1, 2, and 3 “Low 
Symptomatology,” “Moderate Symptomatology,” and “High Symptomatology,” respectively. 
Participants in the Low Symptomatology (N=436) class experienced 6 or fewer symptoms prior to 
their diagnosis (median: 2) while Moderate Symptomatology cases (N=397) reported experiencing 
2 to 12 symptoms (median: 6) and High Symptomatology cases (N=69) 10 to 20 symptoms 
(median: 13). 
When LCA was repeated separately for early and late stage cases we observed that 3-class 
models best fit that data as well. Figures 5 and 6 present the probability of experiencing each 
symptom according to class for early stage cases and late stage cases, respectively. Similarly to 
the LCA results using all study participants, classes for the early stage and the late stage models 
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were largely defined by the total number of symptoms experienced prior to diagnosis and were 
therefore also labeled Low Symptomatology (early/late: N=163/N=256), Moderate 
Symptomatology (early/late: N=170/N=192), and High Symptomatology (early/late: N=25/N=61) 
classes. Among early stage cases, the Low Symptomatology class had a range of 0 to 5 symptoms, 
and the Moderate and High Symptomatology classes reported experiencing 3 to 12 symptoms and 
10 to 20 symptoms, respectively. Among late stage cases, the total number of symptoms in each 
class ranged from 0 to 6, 2 to 12, and 7 to 17, respectively. 
Associations between demographic, lifestyle and disease characteristics and class 
membership among all study participants are presented in Table 9. Significant associations were 
observed between class membership and study site, age, and oral contraceptive use. Similar 
significant associations were observed when limiting analyses to late stage cases only (Table 10). 
In analyses limited to early stage, study site, age and oral contraceptive use were not significant. 
However, smoking status and tumor type were significantly associated with class membership 
among early stage cases only (Table 11). 
3.5 DISCUSSION 
In line with previous studies,78,112,143,144,151,152 the majority of both early and late stage cases within 
our study population experienced at least one symptom prior to their diagnosis. Importantly, we 
found that only a small proportion of participants (13%) were aware of the symptoms associated 
with OC before their diagnosis. This is consistent with the results from a previous study that 
reported that only 15% of the women in a national survey were familiar with OC symptoms.153 
Despite the low awareness of OC symptoms among women, the majority of our cases reported that 
46 
symptoms were the primary reason for making the provider visit that led to their diagnosis, which 
is in agreement with previous findings.152 This suggests that increased awareness of the symptoms 
associated with OC may prompt more women to seek medical attention during the earlier stages 
of disease progression. 
Similar to others, we observed that women with invasive tumors were significantly more 
likely to have experienced at least 1 symptom prior to their diagnosis compared to borderline 
tumors.112,144,151,152 The symptoms most frequently reported by HOPE cases were bloating, weight 
gain or loss, and pelvic or abdominal discomfort and were similar to those reported by OC cases 
in previous studies.108,143,152,154,155 Of the 23 symptoms included in our analysis, only three were 
more likely to be reported by late stage cases than early stage cases (abdominal swelling, distended 
abdomen, and decreased appetite). These results are in agreement with previous studies that found 
that these symptoms are generally more common among women diagnosed with late stage 
disease.108,112,144,152 Consistent with findings by Lurie et al and Webb et al,109,144 participants 
diagnosed with early stage OC reported experiencing abnormal bleeding and abdominal mass 
significantly more often than participants with late stage disease; however, Vine et al did not 
observe the same associations.152  
Using LCA, we determined that there were 3 distinct groups of OC cases that differed 
according to symptom experience prior to their diagnosis. Rather than identifying patterns of 
symptoms that frequently occur together, we found that the groups were defined according to the 
total number of symptoms experienced. We also found that the probability of experiencing each 
individual symptom is proportional in that women within the High Symptomatology class had a 
higher probability of experiencing each symptom compared to women in the Moderate and Low 
Symptomatology classes. This was true for all symptoms except for abdominal bloating, 
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abdominal mass, and ‘other’ symptoms. Participants who were in the High Symptomatology group 
had a lower probability of experiencing these symptoms than expected. It is possible that these 
symptoms were more indicative of a serious health problem and prompted women to seek medical 
attention before they developed a greater number of symptoms. Two of these symptoms, 
abdominal bloating and abdominal mass, were significantly more likely to have been reported by 
women with early stage disease. This further supports the idea that women perceived these 
symptoms to require medical attention and therefore resulted in their OC being diagnosed during 
earlier stages of disease progression. These results suggest that raising awareness of the 
seriousness of milder symptoms experienced in combination may also prompt women to seek 
medical attention before their OC progresses to late stage disease. 
We observed a significant difference in class membership according to age. Older women 
were less likely to be in the High Symptomatology class, which may be related to their general 
health status. It is possible that symptoms were less worrisome or noticeable due to comorbidities 
and other health problems associated with increased age, making older women less likely to 
remember experiencing a specific symptom. We also observed a significant association between 
oral contraceptive use and class membership. Lurie et al reported that women who used 
contraceptive hormones were more likely to experience bowel irregularity, bloating, and nausea 
and this finding may support our observation that oral contraceptive use was associated with the 
number of total symptoms experienced.109 Study site was also significantly associated with class 
membership, which may be indicative of interviewer bias. When separately assessing the 
association between class membership and demographic, lifestyle and disease characteristics 
among women with late stage disease, we observed similar results. However, study site, age and 
oral contraceptive use were not associated with class membership when evaluating only early stage 
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cases. Among early stage cases, smoking status was significantly associated with class 
membership, which indicates that smoking may exacerbate or attenuate the severity of symptoms 
associated with early stage OC. Tumor type also significantly differed according to class 
membership among early stage cases. This suggests that during early stages of disease some tumor 
types may be associated with experiencing a greater number of symptoms than other tumor types.  
However, generally, we found that class membership to the Low, Moderate, or High 
Symptomatology classes was not significantly associated with specific participant or disease 
characteristics. This suggests that the total number of symptoms is not sensitive to individual 
characteristics and may improve the specificity of symptom-based screening protocols. Other 
studies have reported that the number of symptoms experienced by OC cases is greater than the 
number of symptoms experienced by healthy women, which provides further evidence that the 
number of symptoms may improve the specificity of symptom indexes.108,109,152,156 In addition, our 
results highlight the diversity of symptoms experienced by OC cases and emphasizes the 
importance of accounting for total number of symptoms when developing symptom-based 
screening methods. 
To our knowledge, this study is the first to utilize LCA to provide further insight into the 
diverse symptoms that are experienced by OC cases prior to their diagnosis. An advantage of using 
LCA to characterize OC symptom presentation is that it is a person-centered method based on 
individual response patterns. By examining many common OC symptoms simultaneously, we 
were able to obtain a more comprehensive assessment of the symptoms experienced by women 
prior to being diagnosed with OC. Another advantage of using LCA is that the identification of 
subgroups is data driven rather than specified by the investigator. Our study was further 
strengthened by our relatively large study population and the availability of clinical, demographic, 
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and lifestyle data. The availability of this information allowed us to determine whether these 
factors were associated with experiencing Low, Moderate, or High Symptomatology prior to 
diagnosis. Additionally, participants were questioned about a large number of symptoms 
previously linked to OC, which enabled us to compare our results with previous studies that 
assessed pre-diagnostic symptom presentation among women with OC. Our study also had several 
limitations. The retrospective design of our study relied on self-reported data and was therefore 
susceptible to recall bias. In addition, cases’ ability to recall the symptoms they experienced prior 
to their diagnosis may have been influenced by their current health status or the effects of 
treatment, although, the use of a reference date and life calendar may have improved accuracy. 
Unfortunately, our questionnaire did not ask healthy controls whether they had experienced 
symptoms prior to the reference date and we were therefore unable to compare the symptom 
presentation among controls to those of cases.  
Our finding that cases can be grouped into Low, Moderate, and High Symptomatology 
classes suggests that symptom screening protocols that are limited to only a few of the symptoms 
linked to OC may be ineffective. Furthermore, our observation that the number of symptoms 
experienced prior to diagnosis did not significantly differ between early and late stage cases also 
provides evidence that the total number of symptoms experienced may improve the ability of 
screening methods to successfully identify women with early stage OC. Future efforts to educate 
women about OC-related symptoms should emphasize that symptoms frequently occur in 
combination. The resulting increased awareness of symptom presentation may prompt more 
women to seek medical attention during the early stages of OC thereby improving overall survival. 
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3.6 TABLES 
Table 5. Selected demographic and disease characteristics of the study 
population (Ntotal=902)
Study Site N % 
Buffalo 251 27.8 
Cleveland 294 32.6 
Pittsburgh 357 39.6 
Age (years)  
< 45 125 13.9 
45 < 55 227 25.2 
55 <65 261 28.9 
≥ 65 289 32.0 
Race 
Caucasian 856 94.9 
African-American 35 3.9 
Other 11 1.2 
Family History 
No 715 79.3 
Breast cancer only 147 16.3 
Ovarian cancer only 32 3.6 
Breast and ovarian cancers 8 0.9 
Education 
Non-high school graduate 83 9.2 
High school graduate 303 33.6 
Post-high school 516 57.2 
Menopausal Status 
Pre-menopausal 234 25.9 
Post-Menopausal 668 74.1 
Type of Cancer
Ovarian, borderline 97 10.7 
Ovarian, invasive 677 75.1 
Peritoneal 75 8.3 
Fallopian 32 3.5 
Other / unknown 21 2.3 
Tumor Type 
Brenner 4 0.4 
Clear cell 54 6.0 
Endometrioid 100 11.1 
Mucinous 66 7.3 
Serous 516 57.2 
Mixed 77 8.5 
Other/ unknown a * 85 7.9 
Grade 
Borderline tumor 97 10.8 
Well differentiated 76 8.4 
Moderately differentiated 171  19.0 
Poorly differentiated / undifferentiated 467  51.8 
Other/ unknown 91 10.1 
Stage at Diagnosis b 
I 249 27.6 
II 109 12.1 
III 450 49.9 
IV 59 6.5 
Unknown 35 3.9 
a Includes 11 “Poorly/Undifferentiated,” 56 “Other,” 3 “Non-epithelial” & 15 missing tumor 
type information. 
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Table 6. Diagnosis-related factors of ovarian cancer cases, by stage
All Cases 
N=902 
Early Stage a 
N=358 
Late Stage a 
N=509 
P-value b 
N % N % N % 
Primary reason for provider visit that led to diagnosis c 
Routine gynecologic exam 103 11.4 55 15.4 46 9.0 0.023 
Routine health exam 57 6.3 25 7.0 30 5.9 
Routine screening (CA125, TVU, etc.) 18 2.0 8 2.2 9 1.8 
Symptoms of ovarian cancer 569 63.1 208 58.1 340 66.8 
Pregnancy 7 0.8 5 1.4 2 0.4 
Infertility evaluation 3 0.3 3 0.8 0 0.0 
Hysterectomy 3 0.3 1 0.3 2 0.4 
Other surgery 20 2.2 5 1.4 13 2.6 
Other problem  101 11.2 38 10.6 58 11.4 
Other reason 16 1.8 7 2.0 7 1.4 
Healthcare provider that made the diagnosis 
Gynecological oncologist 480 53.2 208 58.1 261 51.3 < 0.001 
Obstetrician/Gynecologist 197 21.8 97 27.1 94 18.5 
PCP/ General practitioner 107 11.9 15 4.2 84 16.5 
Surgeon 49 5.4 16 4.5 28 5.5 
Infertility specialist 3 0.3 3 0.8 0 0.0 
Other 66 7.3 19 5.3 42 8.3 
Actively seeking treatment to watch for ovarian cancer 
No 835 92.6 331 92.5 471 92.5 0.967 
Yes 67 7.4 27 7.5 38 7.5 
Had annual gynecological exam within a year prior to diagnosis 
No 362 40.1 144 40.2 198 38.9 0.695 
Yes 540 59.9 214 59.8 311 61.1 
Pre-treatment CA-125 d 
< 35 U/mL 114 12.6 86 24.0 23 4.5 < 0.001 
≥ 35 U/mL 574 63.6 182 50.8 375 73.7 
Unknown 214 23.7 90 25.1 111 21.8 
Experienced symptoms prior to diagnosis 
No 63 7.0 33 9.2 29 5.7 0.048 
Yes 839 93.0 325 90.8 480 94.3 
a 35 cases are missing stage information. 
b p-values were obtained using chi-square tests. 
c 5 cases were missing reason for making the provider visit that led to diagnosis. 
d Pre-treatment CA-125 levels were available for 677 (75.1%) of cases. 
e 35 cases were missing stage information. 
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Table 7. Symptoms experienced prior to diagnosis, in order of symptom frequency, stratified by stage and by 
whether symptoms led to diagnosis 
All Cases 
N= 902 
Symptoms 
Led to Their 
Diagnosis a 
N= 569 
Cases That Were 
Diagnosed for a Reason 
Other than Symptoms a
N= 332 
Symptoms Led to Diagnosis vs 
Symptoms did Not Lead to 
Diagnosis a,b 
N= 901 
Early Stage c 
N= 358 
Late Stage c 
N= 509 
Early vs Late Stage b,c 
N=867 
N % N % N % OR (95% CI) N % N % OR (95% CI) 
Symptoms Experienced Prior to Diagnosis  
No symptoms 63 7.0 N/A N/A  N/A N/A N/A 33 9.2 29 5.7 0.6 (0.35, 1.00) 
Bloating 321 35.6 231 40.6 90 27.1 1.84 (1.36, 2.50) 114 31.8 195 38.3 1.33 (1.00, 1.77) 
Weight gain/loss 300 33.3 217 38.1 83 25.0 1.85 (1.36, 2.53) 114 31.8 172 33.8 1.09 (0.82, 1.46) 
Pelvic/abdominal discomfort 299 33.2 224 39.4 75 22.6 2.22 (1.62, 3.07) 118 33.0 167 32.8 0.99 (0.74, 1.32) 
Ongoing fatigue 257 28.5 180 31.6 77 23.2 1.53 (1.11, 2.12) 101 28.2 143 28.1 0.99 (0.74, 1.64) 
Abdominal swelling 251 27.8 190 33.4 61 18.4 2.23 (1.59, 3.14) 73 20.4 167 32.8 1.91 (1.39, 2.62) 
Distended abdomen 238 26.4 179 31.5 59 17.8 2.12 (1.51, 3.01) 78 21.8 147 28.9 1.46 (1.06, 2.00) 
Frequent/urgent urination 223 24.7 151 26.5 72 21.7 1.30 (0.94, 1.83) 101 28.2 116 22.8 0.75 (0.55, 1.02) 
Gas 221 24.5 154 27.1 66 19.9 1.50 (1.07, 2.11) 83 23.2 129 25.3 1.12 (0.82, 1.54) 
Feeling full 215 23.8 149 26.2 66 19.9 1.43 (1.02, 2.02) 81 22.6 125 24.6 1.11 (0.81, 1.53) 
Bowel irregularity 196 21.7 134 23.6 61 18.4 1.37 (0.96, 1.95) 79 22.1 107 21.0 0.94 (0.68, 1.31) 
Severe pelvic pain 192 21.3 143 25.1 49 14.8 1.94 (1.34, 2.83) 80 22.4 104 20.4 0.89 (0.64, 1.24) 
Change in how clothes fit 169 18.7 115 20.2 54 16.3 1.30 (0.90, 1.90) 59 16.5 104 20.4 1.30 (0.91, 1.85) 
Indigestion 168 18.6 130 22.8 38 11.4 2.29 (1.53, 3.48) 63 17.6 94 18.5 1.06 (0.75, 1.51) 
Constipation 163 18.1 109 19.2 53 16.0 1.25 (0.86, 1.83) 54 15.1 103 20.2 1.43 (1.00, 2.05) 
Heartburn 154 17.1 110 19.3 44 13.3 1.57 (1.06, 2.35) 62 17.3 87 17.1 0.98 (0.69, 1.41) 
Abnormal bleeding 153 17.0 113 19.9 40 12.0 1.81 (1.21, 2.74) 85 23.7 62 12.2 0.45 (0.31, 0.64) 
Decreased appetite 129 14.3 101 17.8 28 8.4 2.34 (1.49, 3.79) 39 10.9 85 16.7 1.64 (1.09, 2.46) 
Hard abdomen 122 13.5 96 16.9 26 7.8 2.39 (1.49, 3.93) 48 13.4 66 13.0 0.96 (0.65, 1.43) 
Nausea 103 11.4 67 11.8 36 10.8 1.10 (0.70, 1.74) 43 12.0 52 10.2 0.83 (0.54, 1.28) 
Chest pain/respiratory problems 101 11.2 69 12.1 32 9.6 1.29 (0.82, 2.08) 32 8.9 63 12.4 1.44 (0.92, 2.25) 
Painful intercourse d 78 8.7 45 7.9 33 9.9 0.78 (0.47, 1.28) 39 10.9 36 7.1 0.62 (0.39, 1.00) 
Abdominal mass 73 8.1 47 8.3 26 7.8 1.06 (0.63, 1.82) 44 12.3 28 5.5 0.42 (0.25, 0.68) 
Other 175 19.4 102 17.9 73 22.0 0.77 (0.55, 1.10) 67 18.7 105 20.6 1.13 (0.80, 1.59) 
a 5 cases was missing reason for making the provider visit that led to their diagnosis. 
b Odds ratios and corresponding 95% CIs were calculated using the women who did not experience a specific symptom as the reference group. 
c 35 cases were missing stage information. 
d 1 women was missing pic information. 
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Table 8. Number of symptoms experienced prior to diagnosis and the time elapsed between the onset of first symptom and the visit 
that led to the diagnosis of ovarian cancer, stratified by stage and by whether symptoms led to diagnosis
All Cases 
N= 902 
Symptoms 
Led to Their 
Diagnosis a 
N= 569 
Cases That Were 
Diagnosed for a Reason 
Other than Symptoms a
N= 332 
Symptoms Led to Diagnosis vs 
Symptoms did Not Lead to 
Diagnosis a 
Early Stage b 
N= 358 
Late Stage b 
N= 509 
Early vs Late Stage b 
Total Number of Symptoms Experienced 
0 63 7.0 N/A N/A N/A N/A N/A 33 9.2 29 5.7 Reference 
1 119 13.2 66 11.5 53 16.0 Reference 46 12.9 67 13.2 1.66 (0.89, 3.17) 
2 107 11.9 71 12.5 36 10.8 1.58 (0.92, 2.72) 42 11.7 62 12.2 1.68 (0.89, 3.17) 
3 105 11.6 67 11.8 37 11.1 1.45 (0.85, 2.50) 40 11.2 62 12.2 1.76 (0.93, 3.34) 
4 103 11.4 68 12.0 35 10.5 1.56 (0.90, 2.69) 49 13.7 47 9.2 1.09 (0.58, 2.07) 
5 96 10.6 69 12.1 27 8.1 2.05 (1.16, 3.64) 34 9.5 62 12.2 2.08 (1.08, 3.98) 
 6 63 7.0 49 8.6 14 4.2 2.81 (1.40, 5.63) 21 5.9 37 7.3 2.00 (0.96, 4.17) 
7 59 6.5 45 13.2 14 4.2 2.58 (1.28, 5.20) 21 5.9 37 7.3 2.00 (0.96, 4.17) 
≥ 8 187 20.7 134 23.6 53 16.0 2.03 (1.25, 3.29)  72 20.1 106 20.8 1.68 (0.94, 3.00) 
Time elapsed between onset of first symptom and 
the date of the doctor visit that led to the discovery 
of ovarian cancer c 
Had no symptoms 63 7.0 N/A N/A N/A N/A N/A 33 9.2 29 5.7 Reference 
< 1 month 120 13.2 91 16.0 28 8.4 Reference 38 10.6 76 14.9 2.28 (1.21, 4.29) 
1< 3 months 177 19.6 125 22.0 52 15.7 0.74 (0.43, 1.26) 64 17.9 107 21.0 1.90 (1.06, 3.42) 
3 < 6 months 181 20.1 121 13.4 60 18.1 0.62 (0.37, 1.05) 72 20.1 102 20.0 1.61 (0.90, 2.89) 
6 < 9 months 86 9.5 63 21.3 23 6.9 0.84 (0.45, 1.60) 35 9.8 48 9.4 1.56 (0.80, 3.03) 
9 < 12 months 58 6.4 42 7.4 16 4.8 0.81 (0.40, 1.65) 22 6.1 33 6.5 1.71 (0.82, 3.56) 
≥ 12 months 205 22.7 120 21.1 85 25.6 0.43 (0.26, 0.72) 90 25.1 107 21.0 1.35 (0.76, 2.40) 
a 5 cases were missing reason for making the provider visit that led to their diagnosis. 
b 35 cases were missing stage information. 
c 12 cases were missing time elapsed between onset of first symptom and the date of the doctor visit that led to their diagnosis. 
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Table 9. Associations between demographic, lifestyle and disease  characteristics and 
class membership among all study participants(N=902) 
Low Symptomatology 
N=436 
Moderate Symptomatology 
N=397 
High Symptomatology 
N=69 
P-value 
N % N % N % 
Study Site 
NY 155 35.6 87 21.9 9 13.0 <0.001 
OH 119 27.3 146 36.8 29 42.0 
PA 162 37.2 164 41.3 31 44.9 
Age (years)  
< 45 57 13.1 58 14.6 10 14.5 0.003 
45 < 55 94 21.6 103 25.9 30 43.5 
55 < 65 126 28.9 120 30.2 15 21.7 
≥ 65 159 36.5 116 29.2 14 20.3 
Smoking Status 
Never 236 54.1 184 46.4 38 55.1 0.173 
Former 130 29.8 134 33.8 22 31.9 
Current 70 16.1 79 19.9 9 13.0 
Alcohol Use a 
Light (0-7 drinks per week) 372 85.3 317 80.1 56 81.2 0.337 
Moderate (8-14 drinks per week) 34 7.8 45 11.4 8 11.6 
Heavy (15 or more drinks per week) 30 6.9 34 8.6 5 7.3 
BMI (kg/m2)  b 
 < 25 142 32.6 137 34.5 21 30.4 0.835 
25 < 30 128 29.4 120 30.2 19 27.5 
≥ 30 165 37.9 140 35.3 29 42.0 
Family History of Breast/ Ovarian Cancer 
No 336 77.1 323 81.4 56 81.2 0.292 
Breast cancer only 81 18.6 59 14.9 7 10.1 
Ovarian cancer only 15 3.4 12 3.0 5 7.3 
Breast and ovarian cancers 4 0.9 3 0.8 1 1.5 
Oral Contraceptive Use c 
Never 204 46.8 142 35.8 21 30.4 0.003 
< 5 Years 153 35.1 164 41.3 36 52.2 
≥ 5 Years 78 17.9 91 22.9 12 17.4 
Number of Pregnancies 
0 83 19.0 69 17.4 15 21.7 0.952 
1 54 12.4 55 13.9 5 7.3 
2 100 22.9 98 24.7 18 26.1 
3 85 19.5 69 17.4 13 18.8 
4 55 12.6 49 12.3 8 11.6 
≥ 5 59 13.5 57 14.4 10 14.5 
Menopausal Status 
 Pre-Menopausal 108 24.8 105 26.5 21 30.4 0.580 
Post-Menopausal 328 75.2 292 73.6 48 69.6 
Hormone Replacement Therapy 
Never 269 61.7 235 59.2 39 56.5 0.617 
Ever 167 38.3 162 40.8 30 43.5 
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Table 9. (Continued) 
 
  
 Low Symptomatology 
N=436 
Moderate Symptomatology 
N=397 
High Symptomatology 
N=69 
P-value 
 N % N % N %  
Stage          
I 126 28.9 99 24.9 24 34.8 0.246 
II 61 14.0 45 11.3 3 4.4  
III 206 47.3 209 52.6 35 50.7  
IV 28 6.4 28 7.1 3 4.4  
Unknown 15 3.4 16 4.0 4 5.8  
Primary Tumor Type        
Ovarian, borderline 48 11.0 36 9.1 13 18.8 0.243 
Ovarian, invasive 321 73.6 307 77.3 49 71.0  
Peritoneal 39 8.9 32 8.1 4 5.8  
Fallopian 20 4.6 11 2.8 1 1.5  
Other/unknown 8 1.8 11 2.8 2 2.9  
Borderline vs. Invasive Tumor        
Borderline 48 11.0 36 9.1 13 18.8 0.145 
Invasive 380 87.2 350 88.2 54 78.3  
Other/unknown 8 1.8 11 2.8 2 2.9  
Histologic Sub-type        
Serous 255 59.0 222 57.2 39 58.2 0.901 
Endometrioid 46 10.7 48 12.4 6 9.0  
Mucinous 28 6.5 31 8.0 7 10.5  
Clear cell 24 5.6 23 5.9 7 10.5  
Brenner 2 0.5 2 0.5 0 0.0  
Mixed 41 9.4 31 7.8 5 7.3  
Other/unknown 40 9.2 40 10.1 5 7.3  
Grade        
Well differentiated 44 10.1 28 7.1 4 5.8 0.172 
Moderately differentiated 72 16.5 86 21.7 13 18.8  
Poorly differentiated / Undifferentiated 226 51.8 208 52.4 33 47.8  
Borderline malignancy 48 11.0 36 9.1 13 18.8  
Unknown 46 10.6 39 9.8 6 8.7  
Pre-treatment CA-125        
< 35 U/mL 62 14.2 43 10.8 9 13.0 0.533 
≥ 35 U/mL 267 61.2 261 65.7 46 66.7  
Unknown 107 24.5 93 23.4 14 20.3  
a 1 woman was missing weekly alcohol intake information. 
b 1 woman was missing weight information. 
c 1 woman was missing oral contraceptive usage information. 
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Table 10. Associations between demographic, lifestyle and disease characteristics and 
class membership among all early stage cases (N=358) 
Low Symptomatology 
N=163 
Moderate Symptomatology 
N=170 
High Symptomatology 
N=25 
P-value 
N % N % N % 
Study Site 
NY 45 27.6 28 16.5 3 12 0.083 
OH 53 32.5 71 41.8 11 44 
PA 65 39.9 71 41.8 11 44 
Age (years)  
< 45 29 17.8 37 21.8 5 20 0.106 
45 < 55 47 28.8 55 32.4 11 44 
55 < 65 41 25.2 47 27.6 8 32 
≥ 65 46 28.2 31 18.2 1 4 
Smoking Status 
Never 100 61.4 81 47.6 17 68.0 0.020 
Former 43 26.4 51 30.0 7 28.0 
Current 20 12.3 38 22.4 1 4.0 
Alcohol Use a 
Light (0-7 drinks per week) 140 85.9 141 82.9 20 80.0 0.863 
Moderate (8-14 drinks per week) 11 6.7 16 9.4 3 12.0 
Heavy (15 or more drinks per week) 12 7.4 12 7.1 2 8.0 
BMI (kg/m2) b 
 < 25 49 30.1 56 32.9 5 20.0 0.561 
25 < 30 47 28.8 48 28.2 6 24.0 
≥ 30 66 40.5 66 38.8 14 56.0 
Family History of Breast/ Ovarian Cancer 
No 134 82.2 133 78.2 23 92.0 0.054 
Breast cancer only 27 16.6 30 17.7 0 0.0 
Ovarian cancer only 2 1.2 7 4.1 2 8.0 
Breast and ovarian cancers 0 0.0 0 0.0 0 0.0 
Oral Contraceptive Use c 
Never 71 43.6 60 35.3 7 28.0 0.203 
< 5 Years 64 39.3 70 41.2 14 56.0 
≥ 5 Years 27 16.6 40 23.5 4 16.0 
Number of Pregnancies 
0 41 25.2 42 24.7 8 32.0 0.791 
1 25 15.3 24 14.1 1 4.0 
2 42 25.8 38 22.4 6 24.0 
3 28 17.2 30 17.6 3 12.0 
4 14 8.6 21 12.4 5 20.0 
≥ 5 13 8.0 15 8.8 2 8.0 
Menopausal Status 
 Pre-Menopausal 54 33.1 64 37.7 9 36.0 0.689 
Post-Menopausal 109 66.9 106 62.3 16 64.0 
Hormone Replacement Therapy 
Never 107 65.6 118 69.4 17 68.0 0.763 
Ever 56 34.4 52 30.6 8 32.0 
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Table 10. (Continued) 
 
  
 Low Symptomatology 
N=163 
Moderate Symptomatology 
N=170 
High Symptomatology 
N=25 
P-value 
 N % N % N %  
Stage         
I 112 68.7 115 67.6 22 88.0 0.113 
II 51 31.3 55 32.4 3 12.0  
Primary Tumor Type        
Ovarian, borderline 38 23.3 25 14.7 7 28.0 0.010 
Ovarian, invasive 112 68.7 140 82.4 17 68.0  
Peritoneal 0 0.0 1 0.6 1 4.0  
Fallopian 12 7.4 3 1.8 0 0.0  
Other/unknown 1 0.6 1 0.6 0 0.0  
Borderline vs. Invasive Tumor        
Borderline 38 23.3 25 14.7 7 28.0 0.261 
Invasive 124 76.1 144 84.7 18 72.0  
Other/unknown 1 0.6 1 0.6 0 0.0  
Histologic Sub-type        
Serous 65 39.9 42 24.7 9 36.0 0.159 
Endometrioid 31 19.0 45 26.5 4 16.0  
Mucinous 20 12.3 29 17.1 5 20.0  
Clear cell 17 10.4 18 10.6 4 16.0  
Brenner 0 0.0 3 1.8 0 0.0  
Mixed 15 9.2 18 10.6 3 12.0  
Other/unknown 15 9.2 15 8.8 0 0.0  
Grade         
Well differentiated 25 15.3 25 14.7 3 12.0 0.563 
Moderately differentiated 35 21.5 47 27.7 7 28.0  
Poorly differentiated / Undifferentiated 50 30.7 59 34.7 6 24.0  
Borderline malignancy 38 23.3 25 14.7 7 28.0  
Unknown 15 9.2 14 8.2 2 8.0  
Pre-treatment CA-125        
< 35 U/mL 39 23.9 40 23.5 7 28.0 0.062 
≥ 35 U/mL 77 47.2 92 54.1 13 52.0  
Unknown 47 28.8 38 22.4 5 20.0  
a 1 woman was missing weekly alcohol intake information. 
b 1 woman was missing weight information. 
c 1 woman was missing oral contraceptive usage information. 
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Table 11. Associations between demographic, lifestyle and disease characteristics and 
class membership among all late stage cases (N=509) 
Low Symptomatology 
N=256 
Moderate Symptomatology 
N=192 
High Symptomatology 
N=61 
P-value 
N % N % N % 
Study Site 
NY 107 41.8 51 26.6 10 16.4 <0.001 
OH 54 21.1 74 38.5 21 34.4 
PA 95 37.1 67 34.9 30 49.2 
Age (in years)  
< 45 23 9.0 18 9.4 9 14.7 0.001 
45 < 55 40 15.6 44 22.9 21 34.4 
55 < 65 72 28.1 65 33.9 18 29.5 
≥ 65 121 47.3 65 33.9 13 21.3 
Smoking Status 
Never 129 50.4 86 44.8 31 50.8 0.677 
Former 81 31.6 73 38.0 19 31.2 
Current 46 18.0 33 17.2 11 18.0 
Alcohol Use a 
Light (0-7 drinks per week) 213 83.2 157 81.8 46 75.4 0.572 
Moderate (8-14 drinks per week) 28 10.9 19 9.9 9 14.8 
Heavy (15 or more drinks per week) 15 5.9 16 8.3 6 9.8 
BMI (kg/m2) b 
 < 25 86 33.6 69 35.9 26 42.6 0.770 
25 < 30 81 31.6 58 30.2 16 26.2 
≥ 30 89 34.8 65 33.9 19 31.2 
Family History of Breast/ Ovarian Cancer 
No 189 73.8 158 82.3 48 78.7 0.136 
Breast cancer only 50 19.5 29 15.1 9 14.8 
Ovarian cancer only 13 5.1 2 1.0 4 6.6 
Breast and ovarian cancers 4 1.6 3 1.6 0 0.0 
Oral Contraceptive Use c 
Never 125 48.8 73 38.0 14 23.0 0.003 
< 5 Years 83 32.4 79 41.2 32 52.5 
≥ 5 Years 48 18.8 40 20.8 15 24.6 
Number of Pregnancies 
0 34 12.3 24 12.5 10 16.4 0.837 
1 25 9.8 25 13.0 6 9.8 
2 56 21.9 53 27.6 14 23.0 
3 56 21.9 37 19.3 10 16.4 
4 38 14.8 21 10.9 9 14.8 
≥ 5 47 18.4 32 16.7 12 19.7 
Menopausal Status 
 Pre-Menopausal 44 17.2 39 20.3 17 27.9 0.161 
Post-Menopausal 212 82.8 153 79.7 44 72.1 
Hormone Replacement Therapy 
Never 148 57.8 97 50.5 30 49.2 0.223 
Ever 108 42.2 95 49.5 31 50.8 
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Table 11. (Continued) 
 
  
 Low Symptomatology 
N=256 
Moderate Symptomatology 
N=192 
High Symptomatology 
N=61 
P-value 
 N % N % N %  
Stage        
III 227 88.7 168 87.5 55 90.2 0.837 
IV 29 11.3 24 12.5 6 9.8  
Primary Tumor Type        
Ovarian, borderline 10 3.9 5 2.6 6 9.8 0.286 
Ovarian, invasive 193 75.4 158 82.3 45 73.8  
Peritoneal 42 16.4 22 11.5 9 14.8  
Fallopian 9 3.5 6 3.1 1 1.6  
Other/unknown 2 0.8 1 0.5 0 0.0  
Borderline vs. Invasive Tumor        
Borderline 10 3.9 5 2.6 6 9.8 0.154 
Invasive 244 95.3 186 96.9 55 90.2  
Other/unknown 2 0.8 1 0.5 0 0.0  
Histologic Sub-type        
Serous 199 77.7 151 78.7 42 68.9 0.301 
Endometrioid 8 3.1 8 4.2 4 6.6  
Mucinous 5 2.0 3 1.6 1 1.6  
Clear cell 2 0.8 7 3.7 3 4.9  
Brenner 0 0.0 1 0.5 0 0.0  
Mixed 26 10.2 10 5.2 5 8.2  
Other/unknown 16 6.3 12 6.3 6 9.8  
Grade         
Well differentiated 14 5.5 6 3.1 1 1.6 0.116 
Moderately differentiated 35 13.7 36 18.8 11 18.0  
Poorly differentiated / Undifferentiated 178 69.5 133 69.3 36 29.0  
Borderline malignancy 10 3.9 5 2.6 6 9.8  
Unknown 19 7.4 12 6.3 7 11.5  
Pre-treatment CA-125        
< 35 U/mL 17 6.6 5 2.6 1 1.6 0.229 
≥ 35 U/mL 183 71.5 146 76.0 46 75.4  
Unknown 56 21.9 41 21.4 14 23.0  
a 1 woman was missing weekly alcohol intake information. 
b 1 woman was missing weight information. 
c 1 woman was missing oral contraceptive usage information. 
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3.7 FIGURES 
Figure 3. Probability of Experiencing a Symptom According to Class Membership (N=902) 
Figure 4. Probability of Experiencing Total Number of Symptoms According to Class 
Membership (N=902) 
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Figure 5. Probability of Experiencing a Symptom According to Class Membership Among 
Early Stage Cases (N=358) 
Figure 6. Probability of Experiencing a Symptom According to Class Membership Among 
Late Stage Cases (N=509) 
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4.1 ABSTRACT 
Background: Traditional disease-free survival (DFS) does not reflect how prognosis changes over 
time. Conditional DFS accounts for elapsed time since achieving remission and thereby provides 
more relevant prognostic information. The objective of this study was to estimate conditional DFS 
among ovarian cancer (OC) patients who had achieved remission and to identify the demographic, 
lifestyle, disease, and clinical factors that impact DFS. 
Methods: Patients were recruited between 2003 and 2008 as part of the Hormones and Ovarian 
Cancer Prediction (HOPE) case-control study. They were included in the current study if they had 
originally been diagnosed with epithelial cancers of the ovary, fallopian tube, or peritoneum and 
had achieved remission (N=404). Information on demographic and lifestyle factors was collected 
at the time of enrollment; disease, treatment and clinical characteristics were abstracted from 
medical records. DFS was calculated by Kaplan-Meier method.  
Results: Median DFS was 2.54 years (range 0.03-9.96 years) and the 5-year DFS was 44.6%. The 
probability of surviving an additional 5 years without recurrence, conditioned on having already 
survived 1, 2, 3, 4, and 5 years after remission, was 61.9%, 78.6%, 90.7%, 97.3% and 98.1%, 
respectively. Initial differences in DFS at time of remission between age and stage groups 
diminished over time. Backward stepwise Cox regression performed among all cases and among 
only those who had 1 and 2 years of remission yielded models with differing characteristics.  
Conclusions: 5-year DFS estimates improved dramatically for patients who had already achieved 
a period of remission. Characteristics that are predictive of DFS at time of remission lose 
significance as the period of remission increases. 
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Impact: Conditional DFS is a more relevant measure for those OC patients who have already 
achieved a period of remission. It is particularly useful for patients as well as clinicians for 
informing follow-up care decisions.  
4.2 INTRODUCTION 
It is estimated that there will be 22,240 incident cases of ovarian cancer (ovarian cancer) and 
14,030 deaths due to OC in the U.S. in 2013.2 Although patients diagnosed with localized OC have 
an estimated survival rate of 92%, only approximately 15% of the cases are diagnosed at a 
localized stage. The majority of OC cases are diagnosed after the disease has progressed and 
survival rates for regional and distant disease are 72% and 27.3%, respectively.5 In addition to 
stage, disease and clinical characteristics such as tumor histology, 94,157,158 residual disease after 
cytoreductive surgery,94,159-162 and cancer antigen 125 (CA-125) levels during treatment 163-165 
have been shown to impact prognosis.  
Survival estimates are traditionally reported from the time of diagnosis (overall survival) 
or remission (disease free survival; DFS). Although these estimates provide important information 
to clinicians and patients, they are no longer applicable to patients who have survived for a period 
of time after their initial diagnosis and treatment. Conditional survival, which takes into account 
the changing risk of cancer death over time, offers a more accurate estimate of survival for these 
cancer patients. Several studies have previously assessed conditional overall survival among OC 
patients; three studies used data from the Surveillance, Epidemiology, and End Results (SEER) 
database,166-168 and one used data from the European Network for Indicators on Cancer 
(EUNICE).169 These studies found that overall survival estimates improved as time elapsed since 
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diagnosis and that the impact of prognostic factors such as age, stage, and histology diminishes 
over time. Furthermore, their findings provided evidence that survival probabilities change 
significantly when accounting for time elapsed since diagnosis. 
Complete clinical remission is achieved by the majority of OC patients who are treated 
with cytoreductive surgery and platinum-based chemotherapy.83,84 However, most OC survivors 
will eventually relapse.85-88 Surveillance for recurrent disease generally includes physical exams, 
imaging tests, and the close monitoring of CA-125 levels; although, there is controversy regarding 
the effectiveness of these efforts to meaningfully impact disease outcomes.99-101 Results from a 
recent clinical trial suggest that there was no survival benefit to initiating chemotherapy at the time 
CA-125 levels increased compared to delaying treatment until there was clinical evidence of 
disease. Additionally, earlier deterioration of quality of life was observed among women who were 
treated based on rising CA-125 levels alone.104 Therefore, there is a need to provide accurate 
information regarding risk of recurrence to patients so that they are able to make informed 
decisions concerning their follow-up care.  
To our knowledge, no prior studies have assessed conditional DFS among OC patients. 
The objective of this study is to estimate conditional DFS among OC patients who achieved 
remission and to identify the demographic, lifestyle, disease, and clinical factors that impact DFS.  
4.3 MATERIAL AND METHODS 
4.3.1 Study population and data collection 
Patients included in our analysis were enrolled as part of the Hormones and Ovarian Cancer 
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Prediction (HOPE) case-control study, which has previously been described in detail 
elsewhere.50,130,149 The HOPE study includes 902 ovarian, peritoneal, and fallopian tube cases from 
a contiguous region of Western Pennsylvania, Eastern Ohio, and Western New York. Cases were 
diagnosed between February 2003 and December 2008, were at least 25 years old, and were within 
9 months of initial diagnosis at the time of recruitment. All study participants provided informed 
consent. The study was approved by the University of Pittsburgh Institutional Review Board and 
by the human subject committees at each hospital where cases were identified.  
Trained interviewers collected demographic, lifestyle, and medical history information via 
in-person interviews. A reference date of 9 months prior to the interview date was used in an effort 
to identify only the exposures that occurred before cases were diagnosed with cancer. Contact 
information for all clinicians from whom patients received medical care was collected during the 
interview. Follow-up data for HOPE cases has been collected on an on-going basis through annual 
requests for patient’s medical records from their treating physicians since time of recruitment into 
the HOPE study. Information collected includes CA-125 lab results, chemotherapy flow sheets, 
pathology reports, surgical and hospitalization records, imaging results, and oncologist notes. The 
Social Security Death Index (SSDI) and the National Death Index (NDI) are used to collect data 
on vital status as well. For the purposes of this study, the cutoff date for follow-up data collection 
was April 16, 2013. 
Cases were eligible for inclusion in this study if they were recruited from OH or PA and 
had achieved complete clinical remission. Cases with borderline and non-epithelial ovarian, 
peritoneal, or fallopian tube tumors were excluded. Of the 651 cases recruited from OH or PA, 
404 patients fulfilled these criteria and were included in the current analysis. We observed no 
significant differences in demographic and lifestyle factors between included and excluded OH/PA 
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cases [age (P=0.35), race (P=0.08), education (P=0.69), yearly income (P=0.40), body mass index 
(BMI; P=0.34), smoking status (P=0.30), weekly alcohol intake (P=0.92), family history of 
breast/ovarian cancers (P=0.54), menopausal status (P=0.14)]. 
4.3.2 Demographic and lifestyle characteristics 
All demographic and lifestyle characteristics are based on data provided by participants during the 
initial HOPE interview at the time of recruitment. BMI was calculated as weight (kg) at reference 
date divided by height (m) at reference date squared. Participants were considered to be never 
smokers if they had never smoked cigarettes daily for 6 months or more; former smokers if they 
had ever smoked cigarettes daily for 6 months or more but were not smoking daily at the reference 
date; and, current smokers if they had ever smoked cigarettes daily for 6 months or more and were 
smoking daily at the reference date. Alcohol use was quantified by adding the number of wine, 
beer, and hard liquor drinks consumed per week. Participants who consumed less than 7 drinks per 
week were classified as light drinkers, those who consumed 7-14 drinks per week as moderate 
drinkers, and those who reported drinking more than 14 drinks per week as heavy drinkers. Family 
history of ovarian and breast cancers was defined as having at least one reported diagnosis of 
ovarian or breast cancer in a first-degree relative, including biological mother, father, sisters, 
brothers, sons and daughters. Women were classified as postmenopausal if they were 55 years or 
older, reported natural menopause, had used hormone replacement therapy, or reported no 
menstrual periods in the 6 months prior to the reference date. Women were considered to be 
premenopausal if they had never taken hormone replacement therapy, had reported having 
menstrual periods in the 6 months prior to the reference date, and were younger than 55 years 
old.131  
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4.3.3 Disease and clinical characteristics 
Disease and clinical characteristics were abstracted retrospectively from participant medical 
records. Stage, primary cancer site, grade, histology, synchronous primary tumor, and lymph node 
involvement were collected from pathology reports; if this information was not stated in the 
pathology report, data was obtained from other medical records including surgical notes, hospital 
reports, and oncologist notes. Residual disease and debulking status after completion of 
cytoreductive surgery was determined from surgical notes. Cases were considered to be optimally 
debulked if their disease was < 1cm. If residual tumor size was unavailable, they were classified 
as optimally debulked if their surgeon/oncologist declared them to be optimally debulked at the 
time of their cytoreductive surgery. Cytology of ascites/pelvic washings was also obtained from 
pathology reports of either paracentesis of pre-treatment ascites or ascites/pelvic washings 
obtained at the time of primary surgery. The presence of ascites or pleural effusion was determined 
by imaging results. If no scans of the pelvis or chest were available, the presence of ascites or 
pleural effusion was considered to be “could not be assessed.” Pre-treatment CA-125 levels and 
CA-125 levels throughout chemotherapy and follow-up care were abstracted from CA-125 lab 
results and oncologist notes. Chemotherapy agents were categorized into three groups: platinum-
based (carboplatin, cisplatin, oxaliplatin, and abraxane), taxanes (taxol, taxotere, and xyotax), and 
“other” (all other chemotherapy agents, these were: avastin, doxil, topotecan, gemzar, Cytoxan, 
interferon, mytomycin, Erbitux, ifosphomaide, catumaxomab, and ovarex). Many of the “other” 
chemotherapies were given as part of a clinical trial and in some cases it was unclear whether 
participants received placebo or the active agent; cases that were reported to have received the 
placebo were considered to have received no chemotherapy. The total number of cycles received 
for each group was the sum of all neoadjuvant, adjuvant, maintenance, and persistent disease-
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related chemotherapy. Persistent disease was defined as the presence of measurable disease after 
primary treatment and/or a CA-125 level greater than 35 U/mL.  
Date of diagnosis was defined as the date of first positive cytology, in cases with no 
available cytology prior to primary surgery, the date of primary surgery was used as the date of 
diagnosis. The date of remission was the date that an oncologist first declared them to have no 
evidence of disease. If cases were missing oncologist notes in the interval immediately after 
completion of primary treatment, the first negative surgical result was used. If this too was 
unavailable, the date of remission was the date of first negative imaging results. Among the women 
who were missing the above information, a date of 4 weeks after completion of their adjuvant 
chemotherapy was used. In situations where the only available date did not specify a day, the 15th 
was assigned (N=8). If cases recurred, a similar process was used to determine the date of 
recurrence. If available, the date first diagnosed by an oncologist was used; in instances where this 
was not available, the date of first surgical, imaging or initiation of chemotherapy/radiation was 
used, respectively. Overall survival was defined as the time elapsed between date of diagnosis and 
date of death or last contact. DFS was defined as the interval between the date of remission and 
the date of recurrence or the date of last contact. Patients who were not diagnosed with recurrent 
disease during the period of follow-up data collection were censored at the date of last contact.  
 
4.3.4 Statistical analysis 
Chi-square tests were used to assess differences in demographic and lifestyle characteristics 
between included and excluded OH/PA cases. Traditional overall and DFS estimates were 
calculated using the Kaplan-Meier approach.170 Log-rank tests were used to determine whether 
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survival differed according to demographic, lifestyle, disease and clinical characteristics. 
Conditional DFS was also estimated using Kaplan-Meier methods, conditioning on survival at 1, 
2, 3, 4, and 5 years after achieving remission. For example, to estimate conditional survival at year 
1, we used Kaplan-Meier methods to calculate DFS among only the participants who were disease-
free at 1 year after the date of remission. Participants that had recurred prior to the 1-year time 
point were excluded from the analysis. The impact of demographic, lifestyle, disease and clinical 
characteristics at baseline and at 1, 2, 3, 4, and 5 years after achieving remission were assessed 
through the calculation of hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) 
using Cox regression. Improvements in conditional survival over time were assessed by comparing 
5-year DFS estimates at 1, 2, 3, 4, and 5 years after achieving remission to baseline 5-year DFS. 
Backward stepwise Cox regression was used to identify models of the demographic, lifestyle, 
disease, and clinical factors that impact disease-free survival at baseline and 1, 2, 3, 4, and 5 years 
after remission was achieved. Age (continuous) was locked into the stepwise models with 
entrance/exit tolerance P-values of 0.05 and 0.10, respectively. 
All significance tests were two-sided; P-values < 0.05 were considered statistically 
significant. All analyses were conducted using Stata version 12.1.132  
4.4 RESULTS 
Characteristics of the study population are presented in Table 12. The cohort consisted primarily 
of Caucasian women and most participants had at least some post-high school education. At the 
time of diagnosis, the median age was 58.6 years (range 24-90) and the majority of women were 
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post-menopausal. Only 5.5% of the women had a family history of ovarian cancer or a combination 
of ovarian and breast cancers.  
Table 13 presents the disease and clinical characteristics for patients at baseline (i.e., at 
original diagnosis) as well as at 1, 2, 3, 4, and 5 years after achieving remission, given that they 
remained in remission at these time points. At baseline, the majority was diagnosed with primary 
ovarian tumors, the most common histologic subtype was serous, and most tumors were 
moderately or poorly differentiated. A small percentage of the cohort was diagnosed with a 
synchronous primary tumor (6.5%), the majority of which were endometrial tumors. Only three 
women in the cohort did not undergo cytoreductive surgery and most women were optimally 
debulked (76.0%); furthermore, a large proportion of the cohort had no residual disease at the 
conclusion of their cytoreductive surgery (59.4%). The majority of women received 3 ≤ 6 cycles 
of platinum-based and/or taxane chemotherapy and only a small percentage of women received 
“other” chemotherapy agents. Upon completion of their primary treatment, only 3.2% of the 
women had persistent disease.  
Among the 404 women in this study, the median overall survival was 4.50 years after 
diagnosis (range: 0.82 – 9.89 years). At the cutoff date of April 16, 2013, 235 (58.2%) study 
participants were still alive. The median time elapsed between date of diagnosis and date of 
remission was 6.45 months (range: 0 – 26.2). This includes 12 women whose date of diagnosis 
was the date of their cytoreductive surgery, in which there was no residual disease and no further 
primary treatment necessary. Traditional DFS curves, stratified by stage, are depicted in Figure 7. 
Within our study, 222 (55.0%) women were diagnosed with recurrent OC and the median DFS 
was 2.54 years after achieving remission (range: 0.03 – 9.36 years). Using log rank tests to assess 
whether DFS differed according to the participant characteristics presented in Table 12, we found 
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that only age and menopausal status significantly impacted DFS (P-values: 0.02 and 0.01, 
respectively; data not shown). However, menopausal status was no longer significant when 
adjusting for age using Cox regression. Log rank tests were also used to assess the disease and 
clinical characteristics shown in Table 13. We found that survival was significantly different 
according to all disease and clinical characteristics, with the exception of synchronous primary 
tumor (P=0.06). Characteristics associated with better prognosis tended to have a greater 
proportion of women at later time points of DFS and included: early stage, negative cytology of 
ascites/pelvic washings, no residual disease at the completion of cytoreductive surgery, optimal 
debulking, and the normalization of CA-125 without/prior to chemotherapy, (Table 13). Only 
30.8% of the study participants were diagnosed with stage I disease, however, 61.8% of the women 
who survived 5-years without recurrence had stage I disease. Similar relationships were observed 
for histologic subtypes, cytology of ascites/pelvic washings, pre-treatment ascites, lymph node 
involvement, presence of residual disease, residual disease size, and debulking status after 
cytoreductive surgery, and number of chemotherapy cycles before normalization of CA-125 
(Table 13). 
Hazard ratios for disease and clinical characteristics presented in Table 14 were calculated 
using Cox regression models adjusted for age. At baseline, we observed that the following 
characteristics significantly impacted survival: yearly income, family history, stage, primary site 
of cancer, grade, histology, pre-treatment CA-125 levels, pre-treatment pleural effusion, cytology 
of ascites/pelvic washings, pre-treatment ascites, lymph node involvement, presence of residual 
disease, size of residual disease and debulking status upon completion of cytoreductive surgery, 
number of platinum-based, taxane, and other chemotherapy cycles, maintenance chemotherapy, 
number of cycles before CA-125 normalization, and persistent disease. These same characteristics 
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remained significantly associated with survival among women who had already had periods of 
remission of 1 and 2 years, with the exception of pre-treatment CA-125 levels among women at 2 
years of disease-free survival. In addition to pre-treatment CA-125 levels, the following variables 
were no longer significant among women who had survived 3 years without a recurrence: grade, 
pre-treatment pleural effusion, cytology of ascites/pelvic washings, residual disease after 
cytoreductive surgery, number of “other” chemotherapy cycles, and number of cycles before 
normalization. We were unable to assess the association between some characteristics and survival 
among these women due to limitations of strata size. Cox regression adjusting for age was also 
completed among women who had survived 4 and 5 disease-free years; however, the number of 
women in each stratum was too small to yield meaningful results (data not shown). 
At baseline, 5-year DFS was 44.6%. The probability of attaining an additional 5 years 
without recurrence, conditioned on having already achieved 1, 2, 3, 4, and 5 year periods of 
remission, was 61.9%, 78.6%, 90.7%, 97.3% and 98.1%, respectively (Figure 8). Figure 9 
illustrates unadjusted 5-year DFS for women at baseline and for women who had not recurred 1, 
2, 3, 4, and 5 years after achieving remission. DFS estimates improved for all stages as time elapsed 
from the date of remission. Although women with stage III and IV disease had a much lower 5-
year DFS rate at the time of achieving remission, the disparity in 5-year survival estimates 
decreased as more time elapsed from the date of remission. 5-year DFS also improved for all age 
groups as time elapsed since date of remission (Figure 10). Women in older age groups had lower 
5-year DFS compared to younger women at baseline; however, the differences between the age 
groups also decreased as the period of remission increased. 
Backward stepwise Cox regression yielded a model that included age (continuous), yearly 
income, BMI, race, family history, stage, grade, primary site of cancer, cytology of ascites/pelvic 
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washings, residual disease and debulking status after cytoreductive surgery, number of 
chemotherapy cycles before normalization of CA-125, maintenance chemotherapy, number of 
cycles of taxane and “other” chemotherapy. All study participants were included in the model, 
with the exception of the 3 women who did not have cytoreductive surgery. Repeating the process 
among only women who had achieved a period of remission of 1 year, we identified a model that 
included age, synchronous primary cancer, race, education, yearly income, maintenance 
chemotherapy, number of cycles prior to normalization of CA-125, grade, lymph node 
involvement, family history, pre-treatment ascites, cytology of ascites/pelvic washings, pre-
treatment pleural effusion, and stage. Among women who had survived 2 years without recurrence, 
backward stepwise Cox regression included only age, pre-treatment ascites, pre-treatment pleural 
effusion, education, and grade. Both of these models excluded 1 woman who did not have 
cytoreductive surgery. We were unable to perform backward stepwise Cox regression among only 
cases that had achieved 3, 4, and 5 years of remission due to small subgroup sizes.  
4.5 DISCUSSION 
To the best of our knowledge, this is the first study to assess conditional DFS among OC patients. 
Our findings demonstrate that DFS estimates improve dramatically over time and that conditional 
DFS provides more relevant prognostic information than traditional estimates to patients who have 
already achieved a period of remission. Generally, we observed that DFS improves most for 
patients who initially had the poorest prognosis. Similar to previous studies examining conditional 
overall survival among OC patients, we found that the initial differences in DFS at diagnosis 
between age and stage groups diminished over time. 166-168 This was especially evident among 
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stage III/IV cases and cases that were diagnosed after the age of 65. Our findings suggest that the 
time elapsed since remission may be more important than prognostic factors collected at baseline 
when estimating survival among OC survivors. 
At baseline, we observed significant associations between DFS and the majority of disease 
and clinical characteristics included in this study. Our results are in line with previous studies that 
have established these factors as significant predictors of overall or disease-free survival. These 
characteristics included: age,90,93,94 family history,171 stage,89,92 primary site,172, grade,90,92,95 
histology,89,90,94,95pre-treatment CA-125 levels,173,174 pre-treatment pleural effusion,175,176 cytology 
of ascites/pelvic washings,96,177 and pre-treatment ascites.89 Lymph node biopsies/involvement 
also significantly impacted DFS and is consistent with results from previous studies.95,178-180 
Significant associations between DFS and residual disease or debulking status after cytoreductive 
surgery were also significant.89-91,94 Additionally, we found that the number of platinum, taxane, 
and “other” chemotherapy cycles also significantly impacted DFS.87,89,95,181 Although the number 
of maintenance chemotherapy cycles was included in the number of platinum, taxane and “other” 
chemotherapy totals, receiving maintenance chemotherapy compared to not receiving maintenance 
chemotherapy  was  significantly  associated  with DFS.182,183  Results  from  previous studies 
have provided conflicting results regarding the role of maintenance chemotherapy in improving 
overall survival.184-186 The number of chemotherapy cycles before normalization of CA-125 also 
significantly affected DFS.163-165 Persistent disease was significantly associated with DFS in our 
analysis; however, only 13 cases had persistent disease before achieving remission. The majority 
of HOPE cases that were found to have persistent disease after completion of primary therapy were 
excluded from our study because they never achieved remission. 
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Several factors that predicted DFS at baseline were no longer predictive of survival among 
women who had achieved longer periods of remission. When limiting DFS to only women who 
had achieved remission for a period of 1 or 2 years, we found that the same characteristics remained 
significant, with the exception of pre-treatment CA-125 levels among women who had achieved a 
remission period of 2 years. Among women who had survived a remission period of 3 years, grade, 
pre-treatment pleural effusion, cytology of ascites/pelvic washings, residual disease after 
cytoreductive surgery, number of “other” chemotherapy cycles, and number of cycles before 
normalization of CA-125 were also no longer predictive of DFS. The importance of these 
characteristics diminished over time, suggesting that time of remission already achieved provides 
more meaningful prognostic information to OC survivors than survival estimates based on baseline 
characteristics. 
Backward stepwise Cox regression was used to identify the characteristics that together 
predict DFS and exclude characteristics that are interrelated. We identified 15 characteristics that 
should be included in a DFS prediction model among all women who achieved remission. Among 
patients who achieved 1 year of remission, the process yielded a model with 14 characteristics, 
some of which were not included in the baseline model. Furthermore, the backward stepwise Cox 
regression identified only 5 characteristics that were predictive of DFS among survivors who had 
achieved a remission period of 2 years. These results further suggest that prognostic tools based 
on prognostic factors identified through traditional survival estimates at baseline are no longer 
relevant to OC survivors that have achieved a period of remission. 
OC follow-up care is a controversial topic with disagreement over whether increased 
surveillance for recurrent disease is effective in reducing overall survival.99-101,187 Although the 
use of CA-125 for the early detection of recurrent disease has not resulted in meaningful 
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improvements in overall survival,104 a study by Oskay-Oezcelik found that the majority of patients 
believe routine CA-125 testing was the most important factor in determining their cancer 
outcomes.105 Their findings suggest that physician-patient communication regarding the goals and 
efficacy of follow-up care may be insufficient. Improved measures of recurrence risk, such as 
conditional DFS, may help clinicians provide more accurate prognosis information to survivors. 
Tailored risk assessments can then be used to develop individualized follow-up treatment plans. 
The follow-up information collected from the HOPE participants enabled us to examine 
many prognostic characteristics that have not previously been assessed in OC conditional survival 
estimates. Our study was further strengthened by the fact that cases were recruited within a short 
time period, which limited the possibility that survival over time was influenced by changes in 
standard of care. However, this study has also several limitations that should be noted. The small 
sample sizes within subgroups, particularly within histology, chemotherapy regimens and 
persistent disease, resulted in large confidence intervals in our analyses and in the inability to 
estimate DFS for these variables among patients who had achieved 3 years of remission. Lifestyle 
characteristics were collected at the time of enrollment and therefore do not necessarily reflect the 
smoking status, BMI, weekly alcohol intake, or yearly income throughout treatment and follow-
up care. The women included in this study were predominantly Caucasian, had completed at least 
some post-high school education, and had a yearly income of at least $25,000, which does not 
reflect the general U.S. population and therefore limits the generalizability of our study.  
Future research should focus on the development and validation of prognostic tools that 
can be utilized in the clinical setting to inform follow-up care for OC survivors. Our results provide 
evidence that conditional DFS estimates are more meaningful than traditional DFS estimates to 
OC survivors that have already achieved a period of remission. Consequently, future efforts to 
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create prognostic tools that estimate the risk of recurrence for OC survivors should take the period 
of remission already achieved into account. 
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4.6 TABLES 
Table 12. Characteristics of the study population at time of enrollment 
 N=404 
N % 
Study Site 
PA 236 58.4 
OH 168 41.6 
Age (years) 
 < 45 50 12.4 
45 < 55 104 25.7 
55 < 65 117 29.0 
 ≥ 65 133 32.9 
Race 
Caucasian 391 96.8 
African-American 9 2.2 
Other 4 1.0 
Education 
Non-High School Graduate 36 8.9 
High School Graduate 131 32.4 
Post-High School 237 58.7 
Yearly Income 
≥ $90,000 47 11.6 
$50,000 < $90,000 117 29.0 
$25,000 < $50,000 113 28.0 
< $25,000 80 19.8 
Could Not Be Assessed 47 11.6 
Body Mass Index (in kg/m2) 
< 25 151 37.4 
25 < 30 121 29.9 
≥ 30 132 32.7 
Smoking Status 
Never Smoker 202 50.0 
Former Smoker 140 34.7 
Current Smoker 62 15.4 
Alcohol Use (drinks per week) b
≤ 7 338 83.7 
8 ≤ 14 38 9.4 
≥ 15 28 6.9 
Family History 
None 319 79.0 
Breast Only 63 15.6 
Ovarian Only 18 4.5 
Breast and Ovarian 4 1.0 
Menopausal Status 
Pre-menopausal 97 24.0 
Post-menopausal 307 76.0 
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Table 13. Disease and clinical characteristics across years of disease-free survival  
Baseline 
N=404 
1 Year 
N=281 
2 Years 
N=219 
3 Years 
N=185 
4 Years 
N=148 
5 Years 
N=104 
N  % N  % N  % N  % N  (%) N  (%) 
Stagea 
I 124 30.8 118 42.1 112 51.4 108 58.7 89 60.5 64 61.8 
II 44 10.9 37 13.2 31 14.2 28 15.2 25 17.0 19 18.6 
III 205 50.9 113 40.4 69 31.7 44 23.9 30 20.4 17 16.7 
IV 30 7.4 12 4.3 6 2.8 4 2.2 3 2.0 3 2.9 
Primary Site 
Ovarian 341 84.4 239 85.1 189 86.3 165 89.2 130 87.8 94 90.3 
Peritoneal 30 7.4 18 6.4 11 5.0 4 2.2 3 2.0 2 1.9 
Fallopian 28 6.9 22 7.8 17 7.8 15 8.1 14 9.5 7 6.8 
Could Not be assessed 5 1.2 2 0.7 2 0.9 1 0.5 1 0.7 1 1.0 
Grade 
Well differentiated 42 10.4 39 13.9 34 15.5 32 17.3 28 18.9 16 15.5 
Moderately differentiated 104 25.7 76 27.1 59 26.9 51 27.6 39 26.4 29 28.2 
Poorly differentiated 203 50.3 127 45.2 94 42.9 80 43.2 61 41.2 45 43.7 
Mixed 25 6.2 17 6.1 12 5.5 7 3.8 6 4.1 4 2.9 
Could Not be Assessed 30 7.14 22 7.8 20 9.1 15 8.1 14 9.5 10 9.7 
Histology 
Serous 216 53.5 125 44.5 81 37.0 60 32.4 45 30.4 29 28.2 
Endometrioid 68 16.8 60 21.4 52 23.7 51 27.6 38 25.7 32 31.1 
Mucinous 21 5.2 20 7.1 20 9.1 18 9.7 16 10.8 10 8.7 
Clear cell 29 7.2 28 10.0 24 11.0 22 11.9 20 13.5 14 13.6 
Brenner 5 1.2 4 1.4 4 1.8 3 1.6 3 2.0 3 2.9 
MMT 9 2.2 7 2.5 6 2.7 5 2.7 5 3.4 4 3.9 
Mixed 40 9.9 29 10.3 25 11.4 21 11.4 17 11.5 11 10.7 
Otherb 3 0.7 2 0.7 1 0.5 1 0.5 0 0.0 0 0.0 
Could Not Be Assessed 13 3.2 6 2.1 6 2.7 4 2.2 4 2.7 1 1.0 
Pre-treatment CA-125 Levels 
≤ 35 U/mL 60 14.9 54 19.2 49 22.4 45 24.3 38 25.7 28 26.2 
>35 U/mL 274 67.8 178 63.4 136 62.1 112 60.5 94 63.5 68 66.0 
Could Not Be Assessed 70 17.3 49 17.4 34 15.5 28 15.1 16 10.8 8 7.8 
Pre-treatment Pleural Effusion 
No 58 14.4 36 12.8 29 13.2 29 15.7 27 18.2 19 18.5 
Yes 44 10.9 23 8.2 15 6.9 10 5.4 7 4.7 6 5.8 
Could Not Be Assessed 302 74.8 222 79.0 175 79.9 146 78.9 114 77.0 79 75.7 
Cytology of Ascites/Pelvic Washings 
Negative 138 34.2 123 43.8 114 52.1 107 57.8 85 57.4 64 61.2 
Positive 182 45.1 103 36.6 60 27.4 44 23.8 37 25.0 23 22.3 
Atypical 16 4.0 11 3.9 9 4.1 7 3.8 7 4.7 4 3.9 
Could Not Be Assessed 68 16.8 44 15.7 36 16.4 27 14.6 19 12.8 13 12.6 
Pre-treatment Ascites 
No 153 37.9 128 45.6 112 51.1 99 53.5 83 56.1 60 57.3 
Yes 246 60.9 148 52.7 103 47.0 84 45.4 63 42.6 43 41.8 
Could Not Be Assessed 5 1.2 5 1.8 4 1.8 2 1.1 2 1.4 1 1.0 
Lymph Node Involvement 
No Palpable Nodes, No Biopsies 152 37.6 83 29.5 55 25.1 42 22.7 31 21.0 18 17.5 
Palpable Nodes, No Biopsies 6 1.5 5 1.8 1 0.5 0 0.0 0 0.0 0 0.0 
Biopsies Negative 183 45.3 157 55.9 139 63.5 125 67.6 105 71.0 76 72.8 
Biopsies Positive 57 14.1 33 11.7 21 9.6 16 8.7 10 6.8 8 7.8 
Could Not Be Assessed 6 1.5 3 1.1 3 1.4 2 1.1 2 1.4 2 1.9 
Synchronous Primary Tumorc 
No 375 93.5 261 93.2 202 92.7 170 92.4 135 91.8 96 93.1 
Yes, Endometrial 20 5.0 15 5.4 14 6.4 13 7.1 11 7.5 7 6.9 
Yes, Otherd 6 1.5 4 1.4 2 0.9 1 0.5 1 0.7 0 0.0 
Residual Disease after Cytoreductive Surgeryc 
No 238 59.4 199 71.1 176  80.7 160 87.0 132 89.8 95 92.2 
Yes 133 33.2 65 23.2 34 15.6 21 11.4 15 6.1 8 7.8 
Could Be Assessed 30 7.5 16 5.7 8 3.7 3 1.6 0 0.0 0 0.0 
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Table 13. (Continued) 
Baseline 
N=404 
1 Year 
N=281 
2 Years 
N=219 
3 Years 
N=185 
4 Years 
N=148 
5 Years 
N=104 
N  % N  % N  % N  % N  % N  % 
Residual Disease after Cytoreductive Surgery (cm)c
No Residual Disease 238 59.4 201 71.8 178 81.7 161 87.5 132 89.8 95 92.2 
0.1 < 1.0 40 17.5 38 13.6 18 8.3 11 6.0 9 6.1 5 4.9 
1.0 < 2.0 24 6.0 10 3.6 5 2.3 1 0.5 1 0.7 1 1.0 
≥ 2.0  17 4.2 3 1.1 3 1.4 3 1.6 2 1.4 0 0.0 
Could Not Be Assessed 52 13.0 28 10.0 14 6.4 8 4.4 3 2.0 2 2.0 
Debulking at Cytoreductive Surgerye 
Optimal 307 76.0 244 86.8 196 89.5 171 92.5 138 93.2 97 93.2 
Sub-Optimal 57 14.1 22 7.8 12 5.5 7 3.8 4 2.7 2 1.9 
Received neo-adjuvant chemotherapy 27 6.7 9 3.2 8 3.7 5 2.7 4 2.7 3 2.9 
No primary surgery performed 3 0.7 1 0.4 1 0.5 1 0.5 1 0.7 1 1.0 
Could Not Be Assessed 10 2.5 5 1.8 2 0.9 1 0.5 1 0.7 1 1.0 
Platinum Chemotherapy (# of cycles)f
No 31 7.7 28 10.0 28 12.8 25 13.5 21 14.2 13 11.7 
0 ≤ 3  21 5.2 20 7.1 18 8.2 16 8.7 13 8.8 11 10.7 
3 ≤ 6 247 61.1 173 61.6 130 59.4 115 62.2 91 61.5 64 62.1 
> 6  102 25.3 57 20.3 41 18.7 27 14.6 21 14.2 16 15.5 
Yes, Number of Cycles Unknown 3 0.7 3 1.1 2 0.9 2 1.1 2 1.4 0 0.0 
Taxane Chemotherapy (# of cycles)f
No 41 10.2 37 13.2 35 16.0 30 16.2 24 16.2 16 14.6 
0 ≤ 3  24 5.9 21 7.5 20 9.1 17 9.2 16 10.8 13 12.6 
3 ≤ 6 235 58.2 163 58.0 126 57.5 109 58.9 87 58.8 60 58.3 
> 6  99 24.5 55 19.6 34 15.6 25 13.5 19 12.8 15 14.6 
Yes, Number of Cycles Unknown 5 1.2 5 1.8 4 1.8 4 2.2 2 1.4 0 0.0 
Other Chemotherapy (# of cycles)f,g 
No 355 89.0 253 90.0 201 91.8 175 94.6 142 96.0 100 96.1 
0 ≤ 3  3 0.8 5 1.8 3 1.4 2 1.1 1 0.7 1 1.0 
3 ≤ 6 16 4.0 11 3.9 7 3.2 4 2.2 4 2.7 3 2.9 
> 6  21 5.3 10 3.6 8 3.7 4 2.2 1 0.7 0 0.0 
Yes, Number of Cycles Unknown 4 1.0 2 0.7 0 0.0 0 0.0 0 0.0 0 0.0 
Maintenance Chemotherapy 
No 366 90.6 252 89.7 204 93.2 174 94.1 142 96.0 101 97.1 
Yes 38 9.4 29 10.3 15 6.9 11 5.9 6 4.0 3 2.9 
Number of Chemotherapy Cycles Before Normalization of CA-125 
Normalized Without/Prior to Chemotherapy 133 32.9 120 42.7 105 47.9 94 50.8 76 51.4 51 49.0 
Normalized 1 < 3 Cycles 116 28.7 79 28.1 65 29.7 53 28.7 39 26.4 30 28.8 
Normalized 3 < 6 Cycles 80 19.8 37 13.2 21 9.6 15 8.1 13 8.8 7 6.7 
Normalized ≥ 6 Cycles 37 9.2 19 6.8 9 4.1 7 3.8 7 4.7 5 4.8 
Could Not Be Assessed 38 9.4 26 9.3 19 8.7 16 8.7 13 8.8 11 10.6 
Persistent Disease 
No 391 96.8 277 98.6 216 98.6 183 98.9 146 98.7 103 99.0 
Yes 13 3.2 4 1.4 3 1.4 2 1.1 2 1.3 1 1.0 
a 1 case was missing stage information because she never had staging or cytoreductive surgeries and was never formally staged by oncologist. 
b Includes 1 micropapillary serous, 1 adenosquamous, 1 papillary serous with multiple psammoma bodies. 
c Excludes 3 cases that did not have cytoreductive surgery. 
d Includes 1 case of each of the following synchronous cancers: fallopian tube, granulosa cell tumor of the ovary, recurrent breast, gastrointestinal stromal, skin, and 
appendiceal. 
e Cases were considered to be optimally debulked if their disease was < 1cm or their surgeon/oncologist declared them to be optimally debulked at the conclusion of 
their cytreductive surgery. 
f Includes neoadjuvant, adjuvant and maintenance chemotherapies received as well as any chemotherapy received for persistent disease. 
g Includes avastin, doxil, topotecan, gemzar, Cytoxan, interferon, mytomycin, Erbitux, ifosphomaide, catumaxomab, and ovarex. Many of these “other” 
chemotherapies were given as part of a clinical trial and in some cases it was unclear whether participants received placebo or the active agent; cases that were 
reported to have gotten the placebo were considered to have received no chemotherapy. 
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Table 14. Impact of participant characteristics on conditional disease-free survivala 
Baseline 
N=404 
1 Year 
N=281 
2 Years 
N=219 
3 Years 
N=185 
HR (95% CI) b HR (95% CI) b HR (95% CI)b HR (95% CI) b 
Site 
PA  Ref. Ref. Ref. Ref. 
OH 0.98 (0.75, 1.28) 1.13 (0.77, 1.67) 1.09 (0.59, 2.00) 0.91 (0.31, 2.66) 
Race 
Caucasian Ref. Ref. Ref. Ref. 
African-American 0.56 (0.21, 1.50) 0.76 (0.24, 2.41) 1.21 (0.29, 5.11) 2.55 (0.31, 20.94) 
Other 0.51 (0.07, 3.67) 1.04 (0.14, 7.75) --- --- 
Education 
Non-High School Graduate Ref. Ref. Ref. Ref. 
High School Graduate 1.46 (0.87, 2.44) 1.73 (0.76, 3.91) 5.48 (0.72, 41.61) 1.24 (0.14, 11.12) 
Post-High School 1.24 (0.75, 2.07) 1.54 (0.68, 3.43) 4.79 (0.63, 36.29) 1.01 (0.12, 8.76) 
Yearly Income 
≥ $90,000 Ref. Ref. Ref. Ref. 
$50,000 < $90,000 1.55 (0.94, 2.56) 0.88 (0.49, 1.57) 1.16 (0.44, 3.01) --- 
$25,000 < $50,000 1.71 (1.03, 2.84) 0.70 (0.37, 1.32) 0.71 (0.24, 2.12) --- 
< $25,000 1.52 (0.88, 2.59) 0.87 (0.46, 1.70) 1.35 (0.48, 3.79) --- 
Could Be Assessed 1.64 (0.92, 2.94) 0.83 (0.39, 1.76) 1.08 (0.33, 3.55) --- 
Body Mass Index (in kg/m2) 
< 25 Ref. Ref. Ref. Ref. 
25 < 30 1.14 (0.83, 1.57) 0.84 (0.53, 1.35) 0.86 (0.42, 1.78) 0.56 (0.15, 2.18) 
≥ 30 0.95 (0.69, 1.31) 0.68 (0.43, 1.09) 0.67 (0.32, 1.38) 0.78 (0.25, 2.48) 
Smoking Status 
Never Smoker Ref. Ref. Ref. Ref. 
Former Smoker 0.88 (0.66, 1.18) 1.06 (0.69, 1.63) 0.99 (0.51, 1.89) 0.88 (0.29, 2.70) 
Current Smoker 0.94 (0.63, 1.40) 1.28 (0.74, 2.21) 0.96 (0.39, 2.37) 0.81 (0.17, 3.80) 
Alcohol Use (drinks per week) 
≤ 7 Ref. Ref. Ref. Ref. 
8 ≤ 14 0.97 (0.61, 1.55) 0.89 (0.45, 1.78) 1.36 (0.57, 3.24) 3.00 (0.94, 9.60) 
≥ 15 0.91 (0.53, 1.57) 0.80 (0.35, 1.82) 0.33 (0.05, 2.41) 1.13 (0.14, 8.80) 
Family History 
None Ref. Ref. Ref. Ref. 
Breast Only 0.84 (0.58, 1.22) 0.89 (0.53, 1.51) 1.15 (0.55, 2.40) 2.16 (0.74, 6.34) 
Ovarian Only 0.69 (0.34, 1.41) 0.73 (0.27, 1.98) 0.47 (0.06, 3.41) --- 
Breast and Ovarian 3.25 (1.20, 8.83) 4.23 (1.03, 17.44) 13.90 (1.82, 106.24) --- 
Menopausal Status 
Pre-menopausal Ref. Ref. Ref. Ref. 
Post-menopausal 1.14 (0.74, 1.77) 1.13 (0.61, 2.10) 1.11 (0.44, 2.79) 1.41 (0.34, 5.89) 
Stage c 
I Ref. Ref. Ref. Ref. 
II 3.47 (1.71, 7.02) 3.11 (1.26, 7.66) 2.16 (0.51, 9.07) 1.34 (0.14, 12.93) 
III 12.59 (7.38, 21.49) 12.30 (6.35, 23.97) 14.78 (5.74, 38.02) 11.08 (3.07, 39.97) 
IV 16.08 (8.40, 30.77) 11.00 (4.14, 29.21) 4.21 (0.49, 35.39) --- 
Primary Site 
Ovarian Ref. Ref. Ref. Ref. 
Peritoneal 1.70 (1.10, 2.61) 2.73 (1.53, 4.85) 5.33 (2.32, 12.21) --- 
Fallopian 0.78 (0.44, 1.37) 0.94 (0.44, 2.04) 0.65 (0.15, 2.69) 0.81 (0.11, 6.16) 
Could be assessed 1.63 (0.60, 4.43) 1.06 (0.15, 7.72) 3.00 (0.39, 23.06) --- 
Grade 
Well differentiated Ref. Ref. Ref. Ref. 
Moderately differentiated 3.46 (1.56, 7.63) 2.60 (0.99, 6.83) 2.30 (0.48, 10.94) 1.72 (0.15, 19.64) 
Poorly differentiated 5.00 (2.32, 10.74) 3.73 (1.50, 9.36) 4.51 (1.06, 19.28) 6.38 (0.76, 53.21) 
Mixed 4.81 (1.97, 11.73) 4.62 (1.54, 13.86) 7.10 (1.28, 39.21) --- 
Could Not Be Assessed 3.20 (1.29, 7.93) 2.05 (0.62, 6.72) 3.66 (0.67, 20.05) 2.36 (0.14, 38.62) 
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Table 14. (Continued) 
Baseline 
N=404 
1 Year 
N=281 
2 Years 
N=219 
3 Years 
N=185 
HR (95% CI) a HR (95% CI) a HR (95% CI) a HR (95% CI) a 
Histology 
Serous Ref. Ref. Ref. Ref. 
Endometrioid 0.22 (0.13, 0.37) 0.23 (0.12, 0.43) 0.13 (0.04, 0.42) 0.30 (0.08, 1.11) 
Mucinous 0.04 (0.01, 0.28) --- --- --- 
Clear cell 0.20 (0.10, 0.44) 0.30 (0.13, 0.69) 0.19 (0.05, 0.80) --- 
Brenner 0.36 (0.09, 1.47) 0.32 (0.04, 2.30) 0.59 (0.08, 4.36) --- 
MMT 0.44 (0.16, 1.20) 0.40 (0.10, 1.62) 0.39 (0.05, 2.86) --- 
Mixed 0.46 (0.28, 0.75) 0.37 (0.18, 0.77) 0.38 (0.13, 1.08) 0.25 (0.03, 1.92) 
Otherd 1.18 (0.28, 4.91) 1.47 (0.19, 11.23) --- --- 
Could Not Be Assessed 0.87 (0.44, 1.70) 0.39 (0.10, 1.61) 0.87 (0.21, 3.67) 1.63 (0.21, 12.88) 
Pre-treatment CA-125 Levels 
≤ 35 U/mL Ref. Ref. Ref. Ref. 
>35 U/mL 2.93 (1.75, 4.90) 2.36 (1.21, 4.58) 2.27 (0.88, 5.88) 4.90 (0.63, 38.16) 
Could Not Be Assessed 2.95 (1.66, 5.26) 2.99 (1.41, 6.32) 2.25 (0.71, 7.11) 6.46 (0.67, 62.37) 
Pre-treatment Pleural Effusion 
No Ref. Ref. Ref. Ref. 
Yes 1.98 (1.22, 3.23)  3.65 (1.53, 8.73) 16.99 (2.05, 141.55) 6.06 (0.55, 67.22) 
Could Not Be Assessed 0.97 (0.66, 1.44) 1.90 (0.92, 3.95) 7.61 (1.04, 57.73) 2.43 (0.31, 18.87) 
Cytology of Ascites/Pelvic Washings 
Negative Ref. Ref. Ref. Ref. 
Positive 5.49 (3.72, 8.09) 5.59 (3.34, 9.33) 4.67 (2.20, 9.93) 2.42 (0.78, 7.52) 
Atypical 3.20 (1.53, 6.72) 2.92 (0.99, 8.60) 3.10 (0.68, 14.22) --- 
Could Not Be Assessed 3.52 (2.21, 5.59) 3.03 (1.59, 6.04) 3.68 (1.53, 8.86) 2.14 (0.54, 8.56) 
Pre-treatment Ascites 
No Ref. Ref. Ref. Ref. 
Yes 2.84 (2.08, 3.88) 2.76 (1.79, 4.28) 2.97 (1.52, 5.80) 8.25 (1.86, 36.59) 
Could Not Be Assessed 1.09 (0.27, 4.47) 1.99 (0.47, 8.38) 2.54 (0.33, 19.71) --- 
Lymph Node Involvement 
No Palpable Nodes, No Biopsies Ref. Ref. Ref. Ref. 
Palpable Nodes, No Biopsies 1.48 (0.65, 3.38) 5.40 (2.11, 13.83) 6.54 (0.84, 50.99) --- 
Biopsies Negative 0.30 (0.22, 0.42) 0.36 (0.23, 0.58) 0.43 (0.21, 0.88) 0.91 (0.19, 4.43) 
Biopsies Positive 1.16 (0.82, 1.64) 1.41 (0.84, 2.37) 2.06 (0.94, 4.56) 7.41 (1.49, 36.85) 
Could Not Be Assessed 0.59 (0.19, 1.86) --- --- --- 
Synchronous Primary Tumore 
No Ref. Ref. Ref. Ref. 
Yes, Endometrial 0.43 (0.18, 1.04) 0.17 (0.02, 1.20) 0.36 (0.05, 2.64) 0.86 (0.11, 6.61) 
Yes, Otherf 1.20 (0.44, 3.24) 1.62 (0.39, 6.70) --- --- 
Residual Disease after Cytoreductive Surgerye 
No Ref. Ref. Ref. Ref. 
Yes 4.70 (3.50, 6.31) 4.94 (3.24, 7.54) 4.74 (2.46, 9.14) 2.42 (0.66, 8.86) 
Could Not Be Assessed 5.32 (3.40, 8.34) 7.10 (3.78, 13.32) 10.14 (3.75, 27.39) 7.66 (0.92, 63.96) 
Size of Residual Disease after Cytoreductive Surgery (cm)e
No Residual Disease Ref. Ref. Ref. Ref. 
0.1 < 1.0 4.40 (3.12, 6.21) 5.23 (3.22, 8.51) 4.23 (1.96, 10.02) 1.45 (0.18, 11.4) 
1.0 < 2.0 5.64 (3.51, 9.04) 6.90 (3.34, 14.25) 11.16 (3.78, 32.90) --- 
≥ 2.0  6.74 (3.86, 11.78) 1.41 (0.19, 10.22) 2.77 (0.37, 20.57) 8.14 (1.02, 65.24) 
Could Not Be Assessed 4.90 (3.38, 7.13) 5.89 (3.48, 9.94) 5.56 (2.37, 13.04) 4.49 (0.97, 20.66) 
Debulking at Cytoreductive Surgeryg 
Optimal Ref. Ref. Ref. Ref. 
Sub-Optimal 3.78 (2.73, 5.23) 3.41 (2.02, 5.80) 4.62 (2.03, 10.53) 4.81 (1.06, 21.76) 
Received neo-adjuvant chemotherapy 2.98 (1.89, 4.71) 1.31 (0.48, 3.58) 2.50 (0.76, 8.21) 2.61 (0.34, 20.07) 
No primary surgery performed 1.68 (0.41, 6.88) --- --- --- 
Unknown 3.78 (1.92, 7.43) 4.29 (1.56, 11.74) 3.60 (0.49, 26.40) --- 
Platinum Chemotherapy (# of cycles)h 
No Ref. Ref. Ref. Ref. 
0 ≤ 3  2.22 (0.63, 7.86) 3.81 (0.74, 19.62) 2.33 (0.39, 13.97) --- 
3 ≤ 6 5.69 (2.10, 15.39) 6.32 (1.55, 25.87) 2.39 (0.56, 10.16) --- 
> 6  10.06 (3.68, 27.51) 10.82 (2.59, 45.18) 6.65 (1.53, 28.93) --- 
Yes, Number of Cycles Unknown 2.47 (0.28, 22.14) 5.18 (0.47, 57.39) --- --- 
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Table 14. (Continued) 
Baseline 
N=404 
1 Year 
N=281 
2 Years 
N=219 
3 Years 
N=185 
HR (95% CI) a HR (95% CI) a HR (95% CI) a HR (95% CI) a 
Taxane Chemotherapy (# of cycles)h 
No Ref. Ref. Ref. Ref. 
0 ≤ 3 1.50 (0.55, 4.14) 1.34 (0.36, 5.00) 1.66 (0.34, 8.24) --- 
3 ≤ 6 3.53 (1.73, 7.21) 2.97 (1.19, 7.39) 2.15 (0.65, 7.16) --- 
> 6  6.88 (3.32, 14.27) 6.08 (2.37, 15.60) 4.52 (1.28, 16.02) --- 
Yes, Number of Cycles Unknown 1.84 (0.39, 8.67) 2.96 (0.57, 15.30) 2.56 (0.26, 24.77) --- 
Other Chemotherapy (# of cycles)h,i 
No Ref. Ref. Ref. Ref. 
0 ≤ 3  1.01 (0.32, 3.16) 1.53 (0.38, 6.24) --- --- 
3 ≤ 6 1.75 (1.03, 2.98) 2.59 (1.25, 5.36) 3.90 (1.35, 11.00) 3.40 (0.44, 26.30) 
> 6  2.30 (1.40, 3.79) 2.13 (0.93, 4.89) 4.36 (1.54, 12.35) 4.29 (0.54, 34.20) 
Yes, Number of Cycles Unknown 4.67 (1.72, 12.66) 18.18 (4.29, 76.96) --- --- 
Maintenance Chemotherapy 
No Ref. Ref. Ref. Ref. 
Yes 1.80 (1.22, 2.66) 3.53 (2.16, 5.75) 3.44 (1.52, 7.82) 4.41 (1.20, 16.28) 
Number of Chemotherapy Cycles Before Normalization of CA-
125 
Normalized Without/Prior to Chemotherapy  Ref. Ref. Ref. Ref. 
1 < 3 Cycles 2.03 (1.36, 3.06) 1.42 (0.83, 2.43) 1.89 (0.88, 4.08) 2.47 (0.72, 8.43) 
3 < 6 Cycles 4.45 (2.96, 6.71) 3.44 (1.97, 6.01) 3.53 (1.46, 8.55) 4.07 (0.90, 18.31) 
≥ 6 Cycles 4.14 (2.54, 6.74) 3.56 (1.79, 7.11) 1.73 (0.38, 7.87) --- 
Could Not Be Assessed 2.34 (1.39, 3.95) 1.79 (0.88, 3.65) 1.56 (0.50, 4.91) 1.04 (0.12, 9.28) 
Persistent Disease 
No Ref. Ref. Ref. Ref. 
Yes 2.98 (1.58, 5.63) 0.84 (0.12, 6.01) --- --- 
a Please see Tables 1and 2 for the number of participants in each stratum. 
b Hazard ratios were calculated using Cox regression models adjusted for age(continuous). 
c 1 case was missing stage information because she never had staging or cytoreductive surgeries and was never formally staged by oncologist. 
d Includes 1 micropapillary serous, 1 adenosquamous, 1 papillary serous with multiple psammoma bodies. 
e Excludes 3 cases that did not have cytoreductive surgery. 
f Includes 1 case of each of the following synchronous cancers: fallopian tube, granulosa cell tumor of the ovary, recurrent breast, gastrointestinal stromal, skin, 
and appendiceal. 
g Cases were considered to be optimally debulked if their disease was < 1cm or their surgeon/oncologist declared them to be optimally debulked at the 
conclusion of their cytreductive surgery. 
h Includes neoadjuvant, adjuvant and maintenance chemotherapies received as well as any chemotherapy received for persistent disease. 
i Includes avastin, doxil, topotecan, gemzar, Cytoxan, interferon, mytomycin, Erbitux, ifosphomaide, catumaxomab, and ovarex. Many of these “other” 
chemotherapies were given as part of a clinical trial and in some cases it was unclear whether participants received placebo or the active agent; cases that were 
reported to have gotten the placebo were considered to have received no chemotherapy. 
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4.7 FIGURES 
Figure 7. Traditional Disease-Free Survival (N=403) a
1 case was missing stage information because she never had staging or cytoreductive surgeries and was never formally staged by oncologist. 
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Figure 8. Improvements in 5-Year Conditional Disease-Free Survival 
Figure 9. Improvements in 5-Year Conditional Disease-Free Survival, Stratified by Stage a 
a 1 case was missing stage information because she never had staging or cytoreductive surgeries and was never formally staged by oncologist. 
b Stage distribution at baseline: Stage I, 124; Stage II, 44; Stage III, 205; Stage IV, 30. 
c Stage distribution after 1 year of remission: Stage I, 118; Stage II, 37; Stage III, 113; Stage IV, 12. 
d Stage distribution after 2 years of remission: Stage I, 112; Stage II, 31; Stage III, 69; Stage IV, 6. 
e Stage distribution after 3 years of remission: Stage I, 108; Stage II, 28; Stage III, 44; Stage IV, 4.
f Stage distribution after 4 years of remission: Stage I, 89; Stage II, 25; Stage III, 30; Stage IV, 3.
g Stage distribution after 5 years of remission: Stage I, 64; Stage II, 19; Stage III, 17; Stage IV, 3. 
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Figure 10. Improvements in 5-Year Conditional Disease-Free Survival, Stratified by Age 
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5.0 CONCLUSIONS AND PUBLIC HEALTH SIGNIFICANCE 
OC accounts for only 3% of new cancer cases among women in the US; however, it is the 5th 
leading cause of cancer death among women in this country.2 OC is a multifactorial, heterogeneous 
disease for which the etiology is not well understood. However, several risk factors have been 
found to impact the risk of OC. These include age,5 oral contraceptive use,49-52 parity,26-29
breastfeeding,30-33 and tubal ligation. 34-36 The relationship between OC and other risk factors, such 
as fertility drug use, remain poorly understood due to conflicting results from previous studies.26,41-
48 Understanding the relationship between fertility drug use and OC risk is complicated by the fact 
that many women who seek attention for infertility are also more likely to be nulliparous and to 
have never breastfed. Previous studies assessing the association between fertility drug use and the 
risk of OC were unable to account for these and other established OC risk factors. The results from 
the first project of this dissertation provide evidence that fertility drug use does not significantly 
contribute to the risk of OC in the majority of women. However, we did observe an increased risk 
of OC among women who remain nulligravid despite infertility evaluation and fertility drug use. 
This suggests that there may be an underlying biological mechanism associated with the inability 
to conceive that impacts OC risk to a greater extent than fertility drug use. Given the rising rate of 
fertility drug use,116 these results are reassuring for women and their clinicians and build upon the 
results of previous studies. Although we did not observe a significant association between fertility 
drug use and OC risk among the majority of women, it is important to continue to evaluate the 
long-term effects of fertility drugs because this may provide additional insight into OC etiology. 
The prognosis for women diagnosed with OC is poor, with an overall 5-year relative 
survival rate of 44.2%. Women diagnosed with localized disease have much higher estimated 
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survival, 91.5%, but unfortunately, the majority of women are diagnosed once the disease has 
metastasized to regional and distant sites. 5 Earlier diagnosis of OC would likely result in 
significantly improved survival rates; however, screening efforts to diagnosis OC during the early 
stages of disease have so far been ineffective. 106,107 Results from recent studies have provided 
evidence that the majority of women experience symptoms prior to their diagnosis and several 
studies have aimed to develop screening tools that utilize symptoms to identify women at high risk 
of having OC. 108,109,188 However, there is evidence that the implementation of such a tool would 
currently result in a high number of false-positives in the general population.112 Consequently, 
there is a strong need to improve understanding of symptom presentation prior to diagnosis and 
identify factors related to symptom presentation that are able to distinguish between healthy 
women and those with OC. The second project of this dissertation was able to classify women into 
three groups according to their symptom presentation prior to diagnosis: low symptomatology, 
moderate symptomatology, and high symptomatology. These groups were defined largely by the 
total number of symptoms experienced. This suggests that symptom-based screening methods 
should consider the total number of symptoms. Importantly, we observed no significant differences 
in the number of symptoms experienced between early and late stage cases, which provides 
evidence that symptom-based screening methods may be useful in identifying early stage disease. 
Only a small percentage of the women in our study (13%) were aware of the signs and symptoms 
of OC prior to their diagnosis. These results suggest that future efforts to educate women about 
the symptoms of OC should emphasize the seriousness of symptoms when they occur in 
combination. Increased awareness of OC symptom presentation may prompt more women to seek 
medical attention for their symptoms during the early stages of disease progression, resulting in 
improved survival. 
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The current surveillance guidelines for recurrent OC include frequent physical exams, 
imaging tests, and the monitoring of CA-125 levels. 97 However, there is controversy regarding 
the effectiveness of such surveillance to result in improved survival. 98-101 Given the costs of 
medical testing and the negative psychological effects associated with disease surveillance, there 
is a need to create personalized surveillance plans. Our third project aimed to determine whether 
conditional DFS provides more relevant and accurate prognostic information to OC patients and 
their clinicians. Traditional survival estimates are estimated at the time of diagnosis and may not 
be relevant to OC patients who have already survived a period of remission. We observed 
increasing 5-year survival estimates as the time elapsed since the date of remission increased. 
Furthermore, we found that the initial disparities in survival between age and stage groups 
diminished over time. This was especially evident among women with late stage disease and those 
who were diagnosed after the age of 65. The results from this project suggest that the time elapsed 
since remission may be more important than prognostic factors collected at the time of diagnosis 
when estimating DFS among OC patients. More accurate methods to estimate the risk of 
recurrence may help clinicians and patients develop tailored follow-up treatment plans.  
The public health implications of this dissertation include an improved understanding of 
the risk factors associated with OC, symptom presentation of OC prior to diagnosis, and DFS 
among OC patients. Our results have the potential to inform strategies for assessing the risk of 
developing OC, OC early detection, and follow-up care of OC. Improvements in each of these 
areas may lead to lower OC incidence and mortality rates. 
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